-- Table structure for table `node`
--

CREATE TABLE `node` (
  `nid` int(10) unsigned NOT NULL AUTO_INCREMENT,
  `vid` int(10) unsigned DEFAULT NULL,
  `type` varchar(32) CHARACTER SET ascii NOT NULL COMMENT 'The ID of the target entity.',
  `uuid` varchar(128) CHARACTER SET ascii NOT NULL,
  `langcode` varchar(12) CHARACTER SET ascii NOT NULL,
  PRIMARY KEY (`nid`),
  UNIQUE KEY `node_field__uuid__value` (`uuid`),
  UNIQUE KEY `node__vid` (`vid`),
  KEY `node_field__type__target_id` (`type`)
) ENGINE=InnoDB AUTO_INCREMENT=595 DEFAULT CHARSET=utf8mb4 COMMENT='The base table for node entities.';

--
-- Dumping data for table `node`
--

INSERT INTO `node` VALUES (1,7,'initiative','cc59f0dc-aa4f-4ac0-a37e-db745f1fe8db','en'),(305,619,'page','ec6f4fd5-7df8-4006-a419-39b51ff62ebc','en'),(306,314,'initiative','4aebf619-413c-49a1-8379-7ab020cbc57d','en'),(307,315,'initiative','ad086681-bde2-45d5-a266-4fa1f11e6334','en'),(309,318,'initiative','42d4f25f-cb48-4b4d-94e2-775a5b029a05','en'),(310,319,'initiative','70b20041-9f6d-41c5-9258-d670392f4139','en'),(399,408,'indicator','956d0c04-8ac7-4771-98b1-db7a3b705d1b','en'),(400,409,'indicator','a1314ba2-9b6d-467e-958e-12b616af1b57','en'),(401,410,'indicator','331d0813-960b-4610-8aa5-1a5fbe0a0b88','en'),(402,411,'indicator','b6265a29-8b02-4ec8-96cf-46c107494e0e','en'),(403,412,'indicator','bad46823-ea27-4351-bd5b-42966b9703ac','en'),(404,413,'indicator','297815e1-9ef4-4bc4-9850-3820c7e042d6','en'),(405,414,'indicator','6391488c-1261-4267-8431-0fbb3140d2ad','en'),(406,415,'indicator','9aa223a6-634b-4c5b-aff2-4ad921a27852','en'),(407,416,'indicator','329d15e4-4ff4-486a-95b8-ba407e45283a','en'),(408,417,'indicator','0cd44e20-7924-49cd-a265-289e9f6d67ac','en'),(409,418,'indicator','000d3651-2b3c-4f84-9fdf-1099fe8a25ef','en'),(410,419,'indicator','9fc85307-237e-4737-89c1-802478e7770b','en'),(411,420,'indicator','4b38d522-ae2d-4cb6-8d5a-43af022cf401','en'),(412,421,'indicator','c1946c6a-d9e8-4826-80b0-1553d561f379','en'),(413,422,'indicator','7125d9e8-0dfa-4790-8382-58b9223f5a6f','en'),(414,423,'indicator','160400fe-81e2-4b10-8b63-a303b761671b','en'),(415,424,'indicator','337e084d-5608-41ee-8988-451b27314196','en'),(416,425,'indicator','3f4f7924-24a3-4a50-896a-df7e4a8c26de','en'),(417,426,'indicator','ddd68e79-fb67-4d6f-8db4-80346866f0f3','en'),(418,427,'indicator','2eba8b87-44be-4c0b-8527-7315a8e4e1d3','en'),(419,428,'indicator','aff1996e-59d3-49b1-8d49-0eb01098d3e4','en'),(420,429,'indicator','1887561b-4e64-4879-9e8f-eb4bc2412ff5','en'),(421,430,'indicator','f04eb5d2-aceb-4de0-9856-41c7df3a56fb','en'),(422,431,'indicator','ca3e4f0a-6958-4c37-a5bd-ce8cf27f7228','en'),(423,432,'indicator','211ade0a-b90e-4dc0-876a-7e9ed9c6ddc0','en'),(424,433,'indicator','0845bc88-7f68-45c6-906f-a0176e60c10f','en'),(425,434,'indicator','87995b7a-27f5-44ca-9dfb-b741f23bd479','en'),(426,435,'indicator','926f3221-02ed-4ed9-ba71-2fbd2aad10e6','en'),(427,436,'indicator','ad67ac19-dde8-4e29-95ae-51c5e24b7ce0','en'),(428,437,'indicator','42e7c391-4d0e-4ec6-a6a2-08c08af0e4f0','en'),(429,438,'indicator','afd1bf82-0472-4062-9797-fcedd12b163b','en'),(430,439,'indicator','34733030-22a3-4ad0-a74e-f70bd48a9af8','en'),(431,440,'indicator','a4778ebc-9496-487b-b4fe-f4ef63c5297d','en'),(432,441,'indicator','ed853d05-513d-4a3e-b30b-e58d06ebac21','en'),(433,442,'indicator','9db8fa66-1277-4c89-9eae-15e2b5099f3b','en'),(434,443,'indicator','6ffbda23-9d2f-47bc-af80-81316c772257','en'),(435,444,'indicator','7754d3a7-6129-42a3-8c35-c2a9f82de31c','en'),(436,445,'indicator','206f82d0-944a-42ec-b01f-8bc63a5eb8e8','en'),(437,446,'indicator','57670426-370d-4a68-9e4e-0fc2c2fbff83','en'),(438,447,'indicator','98aea8e4-1dcf-4f9b-9306-cb8fdd17f6de','en'),(439,448,'indicator','52f72a51-6c41-4adc-9be4-fc2b8eb91b2e','en'),(440,449,'indicator','4674d3cb-66b5-436f-88f7-8f03e7b618a1','en'),(441,450,'indicator','4148547d-ddbf-4000-9ac0-4a5dc06802bf','en'),(442,451,'indicator','2eee6142-da40-42bc-9f59-026b54307dd6','en'),(443,452,'indicator','48bfb2f0-c5eb-4248-b553-ffe47e04ae95','en'),(444,453,'indicator','01c23235-6878-44d3-a3f3-836f68c256af','en'),(445,454,'indicator','4ddc8df8-b7af-4a2d-b0f7-dea6f196065d','en'),(446,455,'indicator','f8dc620a-49d6-4288-aece-6e536c74c0ae','en'),(447,456,'indicator','831e401b-c207-4fe0-a39c-0f6082d7a619','en'),(448,457,'indicator','d64fa981-dca2-4be3-b548-1f02515f80b1','en'),(449,458,'indicator','d52c09c7-9d8c-4253-8a37-cb7ddbee6916','en'),(450,459,'indicator','5b1014de-0bcc-4ad7-8267-522f65fe8d87','en'),(451,460,'indicator','f9ccee58-3635-4863-a8db-ef302193187e','en'),(452,461,'indicator','c390a9bc-c836-4f2b-a1d3-2cec4b48d9f9','en'),(453,462,'indicator','ea1753b5-9c58-45ec-b2c7-95b618cb3adc','en'),(454,463,'indicator','82ee9f25-979d-4c87-b1de-a44bc1c1917d','en'),(455,464,'indicator','45fb4fa7-6d27-4e1c-8ef6-f3c68725db74','en'),(456,465,'indicator','5e050566-e02b-4b8c-9e6a-cab51126461a','en'),(457,466,'indicator','ac511c4a-aad1-4f6b-a323-ba5ded5a90d4','en'),(458,467,'indicator','194e4996-7884-43b8-ae8d-fcbc5c3f9032','en'),(459,468,'indicator','94172863-fba1-4a65-9f86-ff1b4e970eb0','en'),(460,469,'indicator','e0fecf31-b5cc-48bb-9352-3d6b283e62aa','en'),(461,470,'indicator','2d825697-bcb3-47e7-8894-f592a9f7623b','en'),(462,471,'indicator','14e86fcc-d3fd-440a-9eb6-99d313d1c649','en'),(463,472,'indicator','31fbb985-acd2-490d-ba73-3a6c1b13a034','en'),(464,473,'indicator','dccc3a9e-fb67-41c3-b4b6-ce628be0c8b6','en'),(465,474,'indicator','1548410e-6fb4-496f-9b92-6b3ffff43d08','en'),(466,475,'indicator','877d6e71-57f9-442d-91d6-9046f35facb3','en'),(467,476,'indicator','dbd3760a-5023-4b89-b929-626546c94da9','en'),(468,477,'indicator','9a494aa2-43b6-4799-9974-37f1ed9b3490','en'),(469,478,'indicator','cbcb8b7f-cd40-46ed-b7d1-052783a87497','en'),(470,479,'indicator','3655782b-cc14-491f-951e-a4197ce1369f','en'),(471,480,'indicator','6031a00e-5aa8-4a0a-a481-9813e8c3f810','en'),(472,481,'indicator','83067f61-ed71-4d71-a38b-781e7da13894','en'),(473,482,'indicator','d86381ad-8904-49d1-84d6-be410997289a','en'),(474,483,'indicator','20b9d809-290e-4a48-8d72-8e9b101868af','en'),(475,484,'indicator','ad6d51cb-44b3-4ad0-8fd4-18e38dbfab5e','en'),(476,485,'indicator','064f9794-216d-4747-9d04-bfba7deb7534','en'),(477,486,'indicator','706d4ffb-a3e4-4f7f-9f8c-6fdea33f7fab','en'),(478,487,'indicator','ffaf4372-4261-43d3-a894-3eda06358b50','en'),(479,488,'indicator','a168c0fe-bc22-4db5-9891-0e1b79cf8273','en'),(480,489,'indicator','c0686b11-fbc8-42e0-a065-57721b512ee6','en'),(481,490,'indicator','295767f0-8165-44f5-9e42-18ceb301a8ec','en'),(482,491,'indicator','7d79a196-3bdd-4c3a-8b20-d2e62847c206','en'),(483,492,'indicator','73f42d1f-f580-40f6-8455-49c0f7dd678f','en'),(484,493,'indicator','adfbd72d-40f3-479b-bbed-1a3a72330009','en'),(485,494,'indicator','b71f0394-c51d-4268-bfa8-b13aaf9ab260','en'),(486,495,'indicator','5e844a1d-dd76-428a-9764-81f08b5d533a','en'),(487,496,'indicator','6b78fb7f-aa20-49a3-a532-c6eb4c194f82','en'),(488,497,'indicator','325ef703-4855-4c51-b99c-1639ecae285c','en'),(489,498,'indicator','7fbd4a11-8924-454f-9bd9-9b63ad861a49','en'),(490,499,'indicator','41751630-fb2a-4039-803c-eda8af54abc1','en'),(491,500,'indicator','6f3e81eb-a27e-4636-83b2-5e08b2818ea8','en'),(492,501,'indicator','0ee5b275-6ecd-47ea-b500-57e205ec45bb','en'),(493,502,'indicator','52e6ebcf-181b-4a95-88ee-4ed07391c1b0','en'),(494,503,'indicator','00880fa4-fa38-470c-a84d-a932cf652fd5','en'),(495,504,'indicator','40b9bb7d-c940-46b2-b313-fe652ee79f84','en'),(496,505,'indicator','92d392d0-71f7-4d3a-9c57-ed0394abd925','en'),(497,506,'indicator','28d1736f-9c76-4b8f-ba47-3315fc2a19dd','en'),(498,507,'indicator','dd8ca7a0-377a-4207-821b-dda9aeb99f90','en'),(499,508,'indicator','981ad4f5-07ca-427f-a7d2-6d006429dce8','en'),(500,509,'indicator','fac3850c-3d10-461a-88ab-81c6f3740526','en'),(501,510,'indicator','4f232376-6351-4f1b-b5d6-6db00658bbeb','en'),(502,511,'indicator','f0d9671c-a0ca-44ed-8300-eff6b3ddf97c','en'),(503,512,'indicator','32b100c0-37c1-4f9a-94b4-dc3a52e248bf','en'),(504,513,'indicator','173aea85-11cb-41ad-98b8-77bf33d57dd7','en'),(505,514,'indicator','39747071-c697-4616-957d-d026008b3ffb','en'),(506,515,'indicator','fd8335c9-30b9-4d0e-b6e0-cc388bcf07bf','en'),(507,516,'indicator','33254fe8-da7f-49fa-b223-982ecb1aa645','en'),(508,517,'indicator','8bcb23fb-b950-4691-bfbc-f2f4a0e4666b','en'),(509,518,'indicator','a62f44b5-741f-4251-8505-9b23765488d8','en'),(510,519,'indicator','e05010a1-bb3a-4dd7-8ac6-32be9ee512e4','en'),(512,521,'indicator','d994ad7c-07c7-42f6-bd79-ccb8b7dceaa7','en'),(514,523,'webform','0845b717-4c4a-4ff7-88d1-617adf2decc6','en'),(515,524,'webform','03207287-c4e1-42ce-9f09-3ab5e51f393c','en'),(516,525,'initiative','f8078e31-0200-4822-bc1c-7ccaf4b35d21','en'),(518,528,'initiative','bc7a6307-91eb-4514-96fe-ca0ec6e1ad7a','en'),(519,529,'initiative','95474fd0-fcbb-4719-b6cc-4a6d22e9f8c1','en'),(520,530,'initiative','29659b00-4f22-46cc-b4e7-2c673d7a4d3f','en'),(521,531,'initiative','15f652a9-167e-461a-8b86-d43a1d462930','en'),(522,532,'initiative','68f3254b-2641-42b5-abf5-922ff75ba5cc','en'),(523,533,'initiative','f1aa6b5c-623b-418a-8918-57199c54e4c6','en'),(524,534,'initiative','4a06c25a-dd88-4b15-8224-72cf29283eee','en'),(525,535,'initiative','d2a6cba8-3d18-4b08-a04a-2919efe67873','en'),(526,536,'initiative','c69fb88a-f176-4b28-ba45-5a45be494a0b','en'),(527,537,'initiative','2c9e091d-bdff-464e-8a53-88f9e13cbb4d','en'),(528,538,'initiative','b1374da5-f427-43b9-8370-e96ef24264b3','en'),(529,539,'initiative','92dcad3b-f10c-45a6-aea4-67666c9e47b3','en'),(530,540,'initiative','35eb6da8-884e-49d7-ba77-b0f160d191a2','en'),(531,541,'initiative','01969e02-868a-4f04-a59c-9921e7ad36cf','en'),(532,542,'impact_analysis','fbd43bbc-8bf4-4ff4-b753-c4bee2f06b16','en'),(533,543,'impact_analysis','a70c8545-9146-4876-a87b-c92beae33395','en'),(534,544,'initiative','f9a39f42-8d49-41b5-a9c5-9a1a954ea074','en'),(535,545,'initiative','4848a0b0-17ae-4443-b429-70e1d11ad824','en'),(536,546,'initiative','35061929-d20d-4656-9b07-15349b581e8b','en'),(537,547,'initiative','6be80e88-153b-482b-a870-763d08198db6','en'),(538,548,'initiative','61dcad67-b7ee-474b-9251-378f8add8f4f','en'),(539,549,'initiative','3fca4736-a9c7-40e1-bfdb-c74b235dc286','en'),(540,550,'initiative','33ceb142-61f1-41e7-a698-c7fe49c08d00','en'),(541,551,'initiative','f06ef167-41a3-4001-996f-7d9705c04de6','en'),(542,552,'initiative','c365e687-0efd-4a55-93c9-ba45d03d1b7f','en'),(543,553,'initiative','5bf9ce8c-d6e0-41d2-833a-6b8d4e7a7aee','en'),(544,554,'initiative','b39ae34f-d577-4923-9661-f10b51303b91','en'),(545,555,'initiative','ae5ab77e-8726-4181-a0e6-53d28c21b982','en'),(546,556,'initiative','3652b1a5-be27-4750-bf61-30d2eb602db0','en'),(547,557,'indicator','46df2dc1-e76b-4999-8f17-4b9a25a3e2f1','en'),(548,558,'indicator','7ae1b35c-1587-4e7a-a13b-6963f3252c03','en'),(549,559,'indicator','97328bf9-beda-42e7-9660-1e8a0cae2b62','en'),(550,560,'indicator','aeaf0e70-e786-4c8a-9bbe-4066920d4b77','en'),(551,561,'indicator','a3e4cfce-935e-4bda-9f31-1a9a37da86c8','en'),(552,562,'indicator','3b8fd3ff-4812-4885-ae46-dbb4efdab2c9','en'),(553,563,'indicator','0238e9ed-dd2d-42dd-909b-2837b15926cf','en'),(554,564,'indicator','94982b64-1a06-4c43-9025-7949bc353658','en'),(555,565,'initiative','904879e2-8e5b-4a08-a7b2-657534ef620a','en'),(556,566,'initiative','69e44fa7-d334-40e8-bb7d-aab1e30ba7f7','en'),(557,567,'initiative','c701792b-eca8-4d2d-b773-3fe2cfade150','en'),(558,576,'page','7130e051-03b1-4961-a502-8ac97c72eeb4','en'),(559,577,'impact_analysis','1bf2c343-7c27-4e03-88ff-752831ecaa7b','en'),(560,578,'impact_analysis','72d1940b-da44-40ad-84da-3644e6f8feed','en'),(561,579,'impact_analysis','26d92d35-3971-4ad8-b255-b7ca03d3d6e5','en'),(562,580,'impact_analysis','9f8246db-2e23-48c4-aaa1-1db919e46c78','en'),(563,581,'impact_analysis','03a1f363-d8b6-4e16-9bdd-963a957852b0','en'),(564,582,'initiative','d2740eaa-7feb-4951-9489-e71924d79cb4','en'),(565,583,'impact_analysis','7f732b49-07c5-48ce-84b1-2d77fe8e2b53','en'),(566,584,'impact_analysis','c85e8100-c0b0-493c-bc4d-d38100db80b6','en'),(567,585,'impact_analysis','2419591d-bc44-44c5-99c8-2a9596c08e4b','en'),(568,586,'impact_analysis','15ad3ae7-a588-472a-857d-2b92f72c6ffb','en'),(569,587,'impact_analysis','c1038ae5-c285-4c71-be96-f88c6870ad3f','en'),(572,599,'initiative','fd28f3a6-6d2a-4384-ba22-3e3af7a36edc','en'),(574,601,'impact_analysis','78c45d5e-6673-4f72-b476-470ec97333bc','en'),(575,602,'impact_analysis','67995d82-be0f-4604-971f-4a23f419d3aa','en'),(576,603,'impact_analysis','9e188b69-1c8b-43f2-a919-4f850b9f5255','en'),(577,604,'impact_analysis','04e5dea6-5630-4359-a791-dccd8cc6476d','en'),(578,605,'impact_analysis','4add04e8-ef80-45e3-ae81-e40760afec93','en'),(579,606,'impact_analysis','c6c14613-8275-4f83-92a6-ddddccf1c51c','en'),(580,607,'impact_analysis','9e2bc365-011d-40d1-8fb4-90cc9058f984','en'),(581,608,'impact_analysis','6a05602b-78ce-452e-9d11-1ac3d6634d47','en'),(582,609,'impact_analysis','82a75375-f440-4e3f-b9ca-bcac0c995261','en'),(583,610,'impact_analysis','8715ec2a-6df1-4dd4-81c9-4fe4df8b918e','en'),(584,611,'impact_analysis','8833bc72-bad3-4661-8565-63be0dbcaba7','en'),(585,612,'indicator','930af45b-5fd5-42e0-b3e6-3257a80d8b76','en'),(586,613,'impact_analysis','cb040b38-f22b-4437-bf7e-e02f6f9468e2','en'),(587,614,'impact_analysis','3f093407-f0a3-4227-8032-78530a1f1a8f','en'),(588,615,'impact_analysis','f4dd656a-d6b5-4894-ace9-c3a02d34430d','en'),(589,616,'initiative','c8a046c8-bb65-4857-80b8-a65a9f52de85','en'),(590,617,'initiative','ffe3f311-feb0-4ef8-a628-f6dd58751c35','en'),(591,620,'impact_analysis','334fb62e-2388-41e9-9cd9-eafebb472732','en'),(592,621,'initiative','45cb0abb-97c8-442d-9c75-2a4b6ed18ac9','en'),(593,622,'initiative','77d93ae1-e409-4e87-8ebf-aee2f2fd7849','en'),(594,623,'webform','29e07d24-8c70-4033-90db-1d343460e417','en');

--
-- Table structure for table `node__body`
--

CREATE TABLE `node__body` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `body_value` longtext NOT NULL,
  `body_summary` longtext DEFAULT NULL,
  `body_format` varchar(255) CHARACTER SET ascii DEFAULT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `body_format` (`body_format`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field body.';

--
-- Dumping data for table `node__body`
--

INSERT INTO `node__body` VALUES ('page',0,558,576,'en',0,'<div class=\"contextual-region webform-submission-data webform-submission-data--webform-adherence-questionnaire webform-submission-data--view-mode-html\">\r\n<details class=\"webform-container webform-container-type-details js-form-wrapper form-wrapper seven-details\" data-webform-element-id=\"adherence_questionnaire--criteria_1_vision_and_agenda\" id=\"adherence_questionnaire--criteria_1_vision_and_agenda\" open=\"open\">    <summary role=\"button\" aria-controls=\"adherence_questionnaire--criteria_1_vision_and_agenda\" aria-expanded=\"true\" aria-pressed=\"true\" class=\"seven-details__summary\">Criteria 1: Vision and agenda</summary><div class=\"seven-details__wrapper details-wrapper\">\r\n      <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-have-you-developed-a-shared-vision-mission-for-your-initiative- form-item-have-you-developed-a-shared-vision-mission-for-your-initiative-\" id=\"adherence_questionnaire--have_you_developed_a_shared_vision_mission_for_your_initiative_\">\r\n      <label>1) Have you developed a shared vision/mission for your initiative? </label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-webform-document-file js-form-item form-item js-form-type-item form-type-item js-form-item-please-provide-the-mission-statment-and-related-documents-to-the form-item-please-provide-the-mission-statment-and-related-documents-to-the\" id=\"adherence_questionnaire--please_provide_the_mission_statment_and_related_documents_to_the\">\r\n      <label>1.1) Please provide the mission statement and related documents to the mission.</label>\r\n        {Empty}\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-do-you-have-an-agenda-defining-the-priority-areas-mid-term-and-l form-item-do-you-have-an-agenda-defining-the-priority-areas-mid-term-and-l\" id=\"adherence_questionnaire--do_you_have_an_agenda_defining_the_priority_areas_mid_term_and_l\">\r\n      <label>2) Do you have an agenda defining the priority areas, mid-term and long-term objectives and a set of actions to achieve the objectives of the initiative?</label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-webform-document-file js-form-item form-item js-form-type-item form-type-item js-form-item-_-1-please-provide-the-documents-related-to-the-agenda form-item-_-1-please-provide-the-documents-related-to-the-agenda\" id=\"adherence_questionnaire--2_1_please_provide_the_documents_related_to_the_agenda\">\r\n      <label>2.1) Please provide the documents related to the agenda</label>\r\n        <div class=\"item-list\"><ol><li><div>\r\n<span class=\"file file--mime-application-pdf file--application-pdf\"> <a href=\"https://toolbox.multiact.eu/system/files/webform/adherence_questionnaire/34/MSJournal_TheMultipleSclerosisCareUnit_1352458518807082.pdf\" type=\"application/pdf; length=785305\">MSJournal_TheMultipleSclerosisCareUnit_1352458518807082.pdf</a></span>\r\n</div>\r\n\r\n</li></ol></div>\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-textarea js-form-item form-item js-form-type-item form-type-item js-form-item-could-you-please-describe-how-you-have-defined-the-common-object form-item-could-you-please-describe-how-you-have-defined-the-common-object\" id=\"adherence_questionnaire--could_you_please_describe_how_you_have_defined_the_common_object\">\r\n      <label>3) Could you please describe how you have defined the common objectives, priority areas and set of actions?</label>\r\n        {Empty}\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-webform-checkboxes-other js-form-item form-item js-form-type-item form-type-item js-form-item-which-of-the-following-stakeholders-took-part-in-defining-the-ob form-item-which-of-the-following-stakeholders-took-part-in-defining-the-ob\" id=\"adherence_questionnaire--which_of_the_following_stakeholders_took_part_in_defining_the_ob\">\r\n      <label>3.1) Which of the following stakeholders took part in defining the objectives, priorities and set of actions for your initiative?</label>\r\n        {Empty}\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item--have-you-identified-the-intended-beneficiaries-of-your-research form-item--have-you-identified-the-intended-beneficiaries-of-your-research\" id=\"adherence_questionnaire--_have_you_identified_the_intended_beneficiaries_of_your_research\">\r\n      <label>4) Have you identified the intended beneficiaries of your research initiative?</label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-webform-checkboxes-other js-form-item form-item js-form-type-item form-type-item js-form-item-_-please-indicate-which-of-the-following-stakeholders-are-the-in form-item-_-please-indicate-which-of-the-following-stakeholders-are-the-in\" id=\"adherence_questionnaire--7_please_indicate_which_of_the_following_stakeholders_are_the_in\">\r\n      <label>4.1) Please indicate which of the following (stakeholders) are the intended beneficiaries whom you have identified</label>\r\n        Patients, Patients organizations, patient associations, advocacy organizations, etc., Society individual citizens, civil society organizations and networks, Payers and purchasers, public or private entities responsible for underwriting the costs of health care, Care providers, health and social care organizations and professionals (doctors, nurses, etc.), Industry companies developing and selling health products (drugs, devices, applications, etc.) and services sector\r\n        </div>\r\n\r\n\r\n</div>\r\n</details>\r\n\r\n<details class=\"webform-container webform-container-type-details js-form-wrapper form-wrapper seven-details\" data-webform-element-id=\"adherence_questionnaire--criteria_2_participatory_governance\" id=\"adherence_questionnaire--criteria_2_participatory_governance\" open=\"\">    <summary role=\"button\" aria-controls=\"adherence_questionnaire--criteria_2_participatory_governance\" aria-expanded=\"true\" aria-pressed=\"true\" class=\"seven-details__summary\">Criteria 2: Participatory Governance</summary><div class=\"seven-details__wrapper details-wrapper\">\r\n      <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-have-you-established-a-governance-structure-for-the-ms-care-unit form-item-have-you-established-a-governance-structure-for-the-ms-care-unit\" id=\"adherence_questionnaire--have_you_established_a_governance_structure_for_the_ms_care_unit\">\r\n      <label>5)  Have you established a governance structure for your research initiative?</label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-textarea js-form-item form-item js-form-type-item form-type-item js-form-item-_1-could-you-please-describe-the-different-bodies-in-your-govern form-item-_1-could-you-please-describe-the-different-bodies-in-your-govern\" id=\"adherence_questionnaire--11_could_you_please_describe_the_different_bodies_in_your_govern\">\r\n      <label>5.1) Could you please describe the different bodies in your governance (e.g. boards committees, working groups, teams, others) in your research initiative and describe their functions and composition.</label>\r\n        There is a Governance structure established.<br>\r\n• 2 coordinators (co-chairs)<br>\r\n• A working group which defined the characteristics of a MS Care Unit.<br>\r\n• The general assembly = all partners of the multi stakeholder initiative<br>\r\n• The executive Board\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-webform-checkboxes-other js-form-item form-item js-form-type-item form-type-item js-form-item-__0-which-of-the-following-stakeholders-are-involved-in-the-gove form-item-__0-which-of-the-following-stakeholders-are-involved-in-the-gove\" id=\"adherence_questionnaire--_10_which_of_the_following_stakeholders_are_involved_in_the_gove\">\r\n      <label>5.2) Which of the following stakeholders are involved in the governance board?</label>\r\n        Patients, Care providers, health and social care organizations and professionals (doctors, nurses, etc.), Policy makers EU institutions; national, regional and local policy makers, Industry companies developing and selling health products (drugs, devices, applications, etc.) and services sector, Research and education organizations Research organizations; Universities; Education providers; Foundations; Other research projects\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_2-do-you-have-a-procedure-that-describes-the-roles-and-responsi form-item-_2-do-you-have-a-procedure-that-describes-the-roles-and-responsi\" id=\"adherence_questionnaire--12_do_you_have_a_procedure_that_describes_the_roles_and_responsi\">\r\n      <label>5.3) Do you have a procedure that describes the roles and responsibilities of all (or some of the) stakeholders and decision making processes ?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_-4-do-the-stakeholder-participating-in-the-governance-of-the-in form-item-_-4-do-the-stakeholder-participating-in-the-governance-of-the-in\" id=\"adherence_questionnaire--5_4_do_the_stakeholder_participating_in_the_governance_of_the_in\">\r\n      <label>5.4)Could the stakeholders have different decision power?</label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-textarea js-form-item form-item js-form-type-item form-type-item js-form-item-_5-please-describe form-item-_5-please-describe\" id=\"adherence_questionnaire--15_please_describe\">\r\n      <label>5.4.1) Please describe</label>\r\n        Stakeholders have different decision power. The ECF Board has decision making power. There is an ECF MS initiative Advisory Board.\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_6-when-establishing-the-governance-boards-do-you-take-into-acco form-item-_6-when-establishing-the-governance-boards-do-you-take-into-acco\" id=\"adherence_questionnaire--16_when_establishing_the_governance_boards_do_you_take_into_acco\">\r\n      <label>5.5) When establishing the governance boards do you take into account diversity factors (such as gender, sector, geographical/educational background, language) ?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_8-when-establishing-the-governance-boards-do-you-ensure-the-par form-item-_8-when-establishing-the-governance-boards-do-you-ensure-the-par\" id=\"adherence_questionnaire--18_when_establishing_the_governance_boards_do_you_ensure_the_par\">\r\n      <label>5.6) When establishing the governance boards, do you ensure the participation of disadvantaged stakeholders?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_0-when-establishing-the-governance-boards-do-you-protect-the-in form-item-_0-when-establishing-the-governance-boards-do-you-protect-the-in\" id=\"adherence_questionnaire--20_when_establishing_the_governance_boards_do_you_protect_the_in\">\r\n      <label>5.7) When establishing the governance boards, do you protect the integrity and multi-stakeholder nature of the initiative and ensure that self-interest of stakeholders does not prevail on collective decision-making processes?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_2-when-establishing-the-governance-boards-do-you-maintain-commi form-item-_2-when-establishing-the-governance-boards-do-you-maintain-commi\" id=\"adherence_questionnaire--22_when_establishing_the_governance_boards_do_you_maintain_commi\">\r\n      <label>5.8) When establishing the governance boards, do you maintain commitment and ownership among the participating stakeholders?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n</div>\r\n</details>\r\n\r\n<details class=\"webform-container webform-container-type-details js-form-wrapper form-wrapper seven-details\" data-webform-element-id=\"adherence_questionnaire--criteria_3_effective_stakeholder_engagement_patient_engagement\" id=\"adherence_questionnaire--criteria_3_effective_stakeholder_engagement_patient_engagement\" open=\"\">    <summary role=\"button\" aria-controls=\"adherence_questionnaire--criteria_3_effective_stakeholder_engagement_patient_engagement\" aria-expanded=\"true\" aria-pressed=\"true\" class=\"seven-details__summary\">Criteria 3 : Effective Stakeholder Engagement</summary><div class=\"seven-details__wrapper details-wrapper\">\r\n      <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-beyond-the-stakeholders-involved-in-the-governance-structure-hav form-item-beyond-the-stakeholders-involved-in-the-governance-structure-hav\" id=\"adherence_questionnaire--beyond_the_stakeholders_involved_in_the_governance_structure_hav\">\r\n      <label>6) Beyond the stakeholders involved in the governance structure, have you identified other stakeholders who might be influenced or might influence the initiative? </label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-webform-checkboxes-other js-form-item form-item js-form-type-item form-type-item js-form-item-_-1-could-you-please-describe-the-different-bodies-in-your-gover form-item-_-1-could-you-please-describe-the-different-bodies-in-your-gover\" id=\"adherence_questionnaire--5_1_could_you_please_describe_the_different_bodies_in_your_gover\">\r\n      <label>6.1) Please describe these stakeholders considering the classification of Criteria 2</label>\r\n        Patients, Patients organizations, patient associations, advocacy organizations, etc., Payers and purchasers, public or private entities responsible for underwriting the costs of health care, Industry companies developing and selling health products (drugs, devices, applications, etc.) and services sector, stakeholders dedicated to create a culture to effect and sustain change (e.g. training and development of the needed competencies)\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_7-did-you-differentiate-the-level-of-engagement-of-these-stakeh form-item-_7-did-you-differentiate-the-level-of-engagement-of-these-stakeh\" id=\"adherence_questionnaire--27_did_you_differentiate_the_level_of_engagement_of_these_stakeh\">\r\n      <label>6.2) Did you differentiate the level of engagement of these stakeholders (i.e. involved in specific activities of the initiative such as research group, consulted, informed) according to their relevance to the initiative and other specific characteristics?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_8-do-you-have-a-stakeholder-engagement-strategy-in-place-both-w form-item-_8-do-you-have-a-stakeholder-engagement-strategy-in-place-both-w\" id=\"adherence_questionnaire--28_do_you_have_a_stakeholder_engagement_strategy_in_place_both_w\">\r\n      <label>6.3) Do you have a stakeholder engagement strategy in place? (both with regard to stakeholders involved in the governance and \"external\" stakeholders)</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_0-did-you-perform-a-consultation-process-in-order-to-understand form-item-_0-did-you-perform-a-consultation-process-in-order-to-understand\" id=\"adherence_questionnaire--30_did_you_perform_a_consultation_process_in_order_to_understand\">\r\n      <label>6.4) Did you perform a consultation process in order to understand the needs, expectations and challenges of the stakeholders involved in the initiative in terms of their participation in the initiative?  (both with regard to stakeholders involved in the governance and \"external\" stakeholders)</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_1-did-you-carry-out-an-analysis-to-identify-stakeholders-challe form-item-_1-did-you-carry-out-an-analysis-to-identify-stakeholders-challe\" id=\"adherence_questionnaire--31_did_you_carry_out_an_analysis_to_identify_stakeholders_challe\">\r\n      <label>6.5) Did you carry out an analysis to identify stakeholders challenges and barriers to guarantee genuine participation?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_3-with-regard-to-stakeholder-engagement-do-you-have-a-process-t form-item-_3-with-regard-to-stakeholder-engagement-do-you-have-a-process-t\" id=\"adherence_questionnaire--33_with_regard_to_stakeholder_engagement_do_you_have_a_process_t\">\r\n      <label>6.6) With regard to stakeholder engagement, Do you have a process to guarantee a fair and equitable process that takes into account the limitations that participants might encounter (e.g. cognitive impairment, behavioral issues, fatigue)?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_5-do-you-have-a-process-in-place-to-train-stakeholders-in-order form-item-_5-do-you-have-a-process-in-place-to-train-stakeholders-in-order\" id=\"adherence_questionnaire--35_do_you_have_a_process_in_place_to_train_stakeholders_in_order\">\r\n      <label>6.7) Do you have a process in place to train stakeholders in order to allow their genuine and balanced participation?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_-do-you-engage-patients-in-your-research-innovation-r-i-in-one- form-item-_-do-you-engage-patients-in-your-research-innovation-r-i-in-one-\" id=\"adherence_questionnaire--7_do_you_engage_patients_in_your_research_innovation_r_i_in_one_\">\r\n      <label>7) Do you engage patients in your Research &amp; Innovation (R&amp;I), in one or more of the following steps: - Breaking down boundaries - Research priorities - Steering institutions - Design &amp; plan - Research execution - Evaluation - Translation to community ?</label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-checkboxes js-form-item form-item js-form-type-item form-type-item js-form-item-_8-in-which-of-the-7-steps-research-innovation-r-i-path-do-you-e form-item-_8-in-which-of-the-7-steps-research-innovation-r-i-path-do-you-e\" id=\"adherence_questionnaire--38_in_which_of_the_7_steps_research_innovation_r_i_path_do_you_e\">\r\n      <label>7.1) Please select the steps in which you engage patiens:</label>\r\n        4. Design &amp; plan, 5. Research execution, 7. Translation to community\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_9-do-you-have-a-team-manager-dedicated-to-coordinate-the-patien form-item-_9-do-you-have-a-team-manager-dedicated-to-coordinate-the-patien\" id=\"adherence_questionnaire--39_do_you_have_a_team_manager_dedicated_to_coordinate_the_patien\">\r\n      <label>8) Do you have a team/manager dedicated to coordinate the patient engagement?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_0-do-you-have-indicators-to-measure-the-return-on-patient-engag form-item-_0-do-you-have-indicators-to-measure-the-return-on-patient-engag\" id=\"adherence_questionnaire--40_do_you_have_indicators_to_measure_the_return_on_patient_engag\">\r\n      <label>9) Do you have indicators to measure the “return on patient engagement” for each stakeholder involved in your initiative?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_1-do-you-plan-ad-hoc-training-programs-related-to-the-patient-e form-item-_1-do-you-plan-ad-hoc-training-programs-related-to-the-patient-e\" id=\"adherence_questionnaire--41_do_you_plan_ad_hoc_training_programs_related_to_the_patient_e\">\r\n      <label>10) Do you plan ad-hoc training programs related to the patient engagement, including scope and actions?</label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_2-do-you-have-mechanism-in-place-to-recognize-and-reward-patien form-item-_2-do-you-have-mechanism-in-place-to-recognize-and-reward-patien\" id=\"adherence_questionnaire--42_do_you_have_mechanism_in_place_to_recognize_and_reward_patien\">\r\n      <label>11) Do you have mechanism in place to recognize and reward patients?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_3-do-you-have-dedicated-resources-budget-for-patient-engagement form-item-_3-do-you-have-dedicated-resources-budget-for-patient-engagement\" id=\"adherence_questionnaire--43_do_you_have_dedicated_resources_budget_for_patient_engagement\">\r\n      <label>12) Do you have dedicated resources (budget) for patient engagement?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_4-do-you-perform-an-ethical-assessment-of-your-patient-engageme form-item-_4-do-you-perform-an-ethical-assessment-of-your-patient-engageme\" id=\"adherence_questionnaire--44_do_you_perform_an_ethical_assessment_of_your_patient_engageme\">\r\n      <label>13) Do you perform an ethical assessment of your patient engagement strategy and of its implementation?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n</div>\r\n</details>\r\n\r\n<details class=\"webform-container webform-container-type-details js-form-wrapper form-wrapper seven-details\" data-webform-element-id=\"adherence_questionnaire--criteria_4_efficient_management_and_coordination_of_the_initiati\" id=\"adherence_questionnaire--criteria_4_efficient_management_and_coordination_of_the_initiati\" open=\"\">    <summary role=\"button\" aria-controls=\"adherence_questionnaire--criteria_4_efficient_management_and_coordination_of_the_initiati\" aria-expanded=\"true\" aria-pressed=\"true\" class=\"seven-details__summary\">Criteria 4: Efficient Management and  Coordination of the initiative</summary><div class=\"seven-details__wrapper details-wrapper\">\r\n      <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_4-do-you-have-a-collective-action-plan-in-place-in-order-to-ach form-item-_4-do-you-have-a-collective-action-plan-in-place-in-order-to-ach\" id=\"adherence_questionnaire--14_do_you_have_a_collective_action_plan_in_place_in_order_to_ach\">\r\n      <label>14) Do you have a collective action plan in place in order to achieve the objectives of the initiative?</label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-checkboxes js-form-item form-item js-form-type-item form-type-item js-form-item-_8-if-yes-do-you-have-a-plan-that-defines-the-following-please-t form-item-_8-if-yes-do-you-have-a-plan-that-defines-the-following-please-t\" id=\"adherence_questionnaire--48_if_yes_do_you_have_a_plan_that_defines_the_following_please_t\">\r\n      <label>14.1) Do you have a plan that defines the following: Please tick as appropriate</label>\r\n        Specific actions that different stakeholders commit to implement in order to achieve the objectives of the initiative; , Definition of clear and measurable targets, Presentation of clear project timeline,including deadlines in order to allow participants to hold each other accountable\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-webform-document-file js-form-item form-item js-form-type-item form-type-item js-form-item-_4-2-could-you-provide-some-documentation-in-that-context- form-item-_4-2-could-you-provide-some-documentation-in-that-context-\" id=\"adherence_questionnaire--14_2_could_you_provide_some_documentation_in_that_context_\">\r\n      <label>14.2) Could you provide some documentation in that context?</label>\r\n        <div class=\"item-list\"><ul><li><div>\r\n<span class=\"file file--mime-application-pdf file--application-pdf\"> <a href=\"https://toolbox.multiact.eu/system/files/webform/adherence_questionnaire/34/MSJournal_TheMultipleSclerosisCareUnit_1352458518807082_0.pdf\" type=\"application/pdf; length=785305\">MSJournal_TheMultipleSclerosisCareUnit_1352458518807082_0.pdf</a></span>\r\n</div>\r\n\r\n</li></ul></div>\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_9-do-you-have-a-cost-management-process-in-place-e-g-a-defined- form-item-_9-do-you-have-a-cost-management-process-in-place-e-g-a-defined-\" id=\"adherence_questionnaire--49_do_you_have_a_cost_management_process_in_place_e_g_a_defined_\">\r\n      <label>15) Do you have a cost management process in place (e.g. a defined budget, a cost analysis) that ensures that the initiative has enough resources to reach its objectives?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_0-do-you-ensure-that-the-internal-team-has-solid-skills-to-carr form-item-_0-do-you-ensure-that-the-internal-team-has-solid-skills-to-carr\" id=\"adherence_questionnaire--50_do_you_ensure_that_the_internal_team_has_solid_skills_to_carr\">\r\n      <label>16) Do you ensure that the internal team has solid skills to carry out the activities of the initiative?</label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_1-do-you-maintain-accountability-over-time-keeping-track-of-exp form-item-_1-do-you-maintain-accountability-over-time-keeping-track-of-exp\" id=\"adherence_questionnaire--51_do_you_maintain_accountability_over_time_keeping_track_of_exp\">\r\n      <label>17) Do you maintain accountability over time keeping track of expenses and revenues?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_3-do-you-have-a-process-in-place-to-ensure-that-there-is-a-righ form-item-_3-do-you-have-a-process-in-place-to-ensure-that-there-is-a-righ\" id=\"adherence_questionnaire--53_do_you_have_a_process_in_place_to_ensure_that_there_is_a_righ\">\r\n      <label>18) Do you have a process in place to ensure that there is a right balance between an efficient management process and the opportunities for engaging a wide range of participants? (examples:you have defined rules to take final decision in case a discussion among governance body\'s member has run aground; measures to decrease interdependency between activities, measures to increase robustness, etc.)</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-_5-have-you-developed-a-contingency-plan-risk-management-approac form-item-_5-have-you-developed-a-contingency-plan-risk-management-approac\" id=\"adherence_questionnaire--55_have_you_developed_a_contingency_plan_risk_management_approac\">\r\n      <label>19) Have you developed a contingency plan/risk managment approach?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n</div>\r\n</details>\r\n\r\n<details class=\"webform-container webform-container-type-details js-form-wrapper form-wrapper seven-details\" data-webform-element-id=\"adherence_questionnaire--criterion_5_co_accountability_assessment_\" id=\"adherence_questionnaire--criterion_5_co_accountability_assessment_\" open=\"\">    <summary role=\"button\" aria-controls=\"adherence_questionnaire--criterion_5_co_accountability_assessment_\" aria-expanded=\"true\" aria-pressed=\"true\" class=\"seven-details__summary\">Criterion 5: Co-accountability assessment				</summary><div class=\"seven-details__wrapper details-wrapper\">\r\n      <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-do-you-have-a-monitoring-system-for-the-implementation-of-the-ac form-item-do-you-have-a-monitoring-system-for-the-implementation-of-the-ac\" id=\"adherence_questionnaire--do_you_have_a_monitoring_system_for_the_implementation_of_the_ac\">\r\n      <label>20) Do you have a monitoring system for the implementation of the actions of the initiative and the performance of the initiative itself (ongoing) ?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-have-you-defined-an-assessment-system-that-allow-to-measure-init form-item-have-you-defined-an-assessment-system-that-allow-to-measure-init\" id=\"adherence_questionnaire--have_you_defined_an_assessment_system_that_allow_to_measure_init\">\r\n      <label>21) Have you defined an assessment system that allow to measure initiative’s \"long-term impact”(ex-post) ? </label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-does-this-assessment-involve-stakeholders-in-the-gathering-of-da form-item-does-this-assessment-involve-stakeholders-in-the-gathering-of-da\" id=\"adherence_questionnaire--does_this_assessment_involve_stakeholders_in_the_gathering_of_da\">\r\n      <label>21.1) Does this assessment involve stakeholders in the gathering of data and information ?</label>\r\n        {Empty}\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-does-this-assessment-include-indicators-related-to-the-patient-d form-item-does-this-assessment-include-indicators-related-to-the-patient-d\" id=\"adherence_questionnaire--does_this_assessment_include_indicators_related_to_the_patient_d\">\r\n      <label>21.2) Does this assessment include indicators related to the patient dimension ?</label>\r\n        Yes\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-are-the-monitoring-and-the-assessment-systems-and-the-related-in form-item-are-the-monitoring-and-the-assessment-systems-and-the-related-in\" id=\"adherence_questionnaire--are_the_monitoring_and_the_assessment_systems_and_the_related_in\">\r\n      <label>21.3) Are the monitoring and the assessment systems and the related indicators linked to the objectives of the initiative (link with criteria 1)</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-textarea js-form-item form-item js-form-type-item form-type-item js-form-item-please-describe-how-the-measurement-is-linked-to-the-objectives- form-item-please-describe-how-the-measurement-is-linked-to-the-objectives-\" id=\"adherence_questionnaire--please_describe_how_the_measurement_is_linked_to_the_objectives_\">\r\n      <label>21.4) Please describe how the measurement is linked to the objectives (link with criteria 1)</label>\r\n        {Empty}\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-do-you-publish-a-progress-report- form-item-do-you-publish-a-progress-report-\" id=\"adherence_questionnaire--do_you_publish_a_progress_report_\">\r\n      <label>22) Do you publish a progress report ?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-do-you-communicate-with-stakeholders-about-the-progress-of-the-i form-item-do-you-communicate-with-stakeholders-about-the-progress-of-the-i\" id=\"adherence_questionnaire--do_you_communicate_with_stakeholders_about_the_progress_of_the_i\">\r\n      <label>23) Do you communicate with stakeholders about the progress of the initiative ?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-do-you-have-a-review-process-in-place-to-improve-the-initiative- form-item-do-you-have-a-review-process-in-place-to-improve-the-initiative-\" id=\"adherence_questionnaire--do_you_have_a_review_process_in_place_to_improve_the_initiative_\">\r\n      <label>24) Do you have a review process in place to improve the initiative’s performance and practices (based on the results of the monitoring) ?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n  <div class=\"webform-element webform-element-type-select js-form-item form-item js-form-type-item form-type-item js-form-item-do-you-have-a-process-in-place-to-gather-feedback-from-external- form-item-do-you-have-a-process-in-place-to-gather-feedback-from-external-\" id=\"adherence_questionnaire--do_you_have_a_process_in_place_to_gather_feedback_from_external_\">\r\n      <label>25) Do you have a process in place to gather feedback from external stakeholders and the public? (For example a section on the website for public consultation, organization of specific events, etc.) ?</label>\r\n        No\r\n        </div>\r\n\r\n\r\n</div>\r\n</details>\r\n\r\n\r\n</div>','','full_html');

--
-- Table structure for table `node__comment`
--

CREATE TABLE `node__comment` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `comment_status` int(11) NOT NULL DEFAULT 0 COMMENT 'Whether comments are allowed on this entity: 0 = no, 1 = closed (read only), 2 = open (read/write).',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field comment.';

--
-- Dumping data for table `node__comment`
--


--
-- Table structure for table `node__field_admin_panel`
--

CREATE TABLE `node__field_admin_panel` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_admin_panel_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_admin_panel_value` (`field_admin_panel_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_admin_panel.';

--
-- Dumping data for table `node__field_admin_panel`
--

INSERT INTO `node__field_admin_panel` VALUES ('webform',0,594,623,'en',0,'yes');

--
-- Table structure for table `node__field_aspect`
--

CREATE TABLE `node__field_aspect` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_aspect_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the target entity.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_aspect_target_id` (`field_aspect_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_aspect.';

--
-- Dumping data for table `node__field_aspect`
--

INSERT INTO `node__field_aspect` VALUES ('impact_analysis',0,532,542,'en',0,15),('impact_analysis',0,533,543,'en',0,16),('impact_analysis',0,559,577,'en',0,17),('impact_analysis',0,560,578,'en',0,67),('impact_analysis',0,561,579,'en',0,97),('impact_analysis',0,562,580,'en',0,67),('impact_analysis',0,563,581,'en',0,74),('impact_analysis',0,565,583,'en',0,17),('impact_analysis',0,566,584,'en',0,96),('impact_analysis',0,567,585,'en',0,79),('impact_analysis',0,568,586,'en',0,72),('impact_analysis',0,569,587,'en',0,180),('impact_analysis',0,574,601,'en',0,98),('impact_analysis',0,575,602,'en',0,75),('impact_analysis',0,576,603,'en',0,19),('impact_analysis',0,577,604,'en',0,181),('impact_analysis',0,578,605,'en',0,67),('impact_analysis',0,579,606,'en',0,86),('impact_analysis',0,580,607,'en',0,73),('impact_analysis',0,581,608,'en',0,70),('impact_analysis',0,582,609,'en',0,74),('impact_analysis',0,583,610,'en',0,73),('impact_analysis',0,584,611,'en',0,73),('impact_analysis',0,586,613,'en',0,180),('impact_analysis',0,587,614,'en',0,262),('impact_analysis',0,588,615,'en',0,262),('impact_analysis',0,591,620,'en',0,182);

--
-- Table structure for table `node__field_aspect_group`
--

CREATE TABLE `node__field_aspect_group` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_aspect_group_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the target entity.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_aspect_group_target_id` (`field_aspect_group_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_aspect_group.';

--
-- Dumping data for table `node__field_aspect_group`
--

INSERT INTO `node__field_aspect_group` VALUES ('impact_analysis',0,532,542,'en',0,24),('impact_analysis',0,533,543,'en',0,25),('impact_analysis',0,559,577,'en',0,26),('impact_analysis',0,560,578,'en',0,108),('impact_analysis',0,561,579,'en',0,165),('impact_analysis',0,562,580,'en',0,108),('impact_analysis',0,563,581,'en',0,124),('impact_analysis',0,565,583,'en',0,26),('impact_analysis',0,566,584,'en',0,163),('impact_analysis',0,567,585,'en',0,130),('impact_analysis',0,568,586,'en',0,119),('impact_analysis',0,569,587,'en',0,184),('impact_analysis',0,574,601,'en',0,167),('impact_analysis',0,575,602,'en',0,125),('impact_analysis',0,576,603,'en',0,30),('impact_analysis',0,577,604,'en',0,186),('impact_analysis',0,578,605,'en',0,108),('impact_analysis',0,579,606,'en',0,140),('impact_analysis',0,580,607,'en',0,121),('impact_analysis',0,581,608,'en',0,113),('impact_analysis',0,582,609,'en',0,124),('impact_analysis',0,583,610,'en',0,121),('impact_analysis',0,584,611,'en',0,123),('impact_analysis',0,586,613,'en',0,184),('impact_analysis',0,587,614,'en',0,263),('impact_analysis',0,588,615,'en',0,263),('impact_analysis',0,591,620,'en',0,185);

--
-- Table structure for table `node__field_associated_terms`
--

CREATE TABLE `node__field_associated_terms` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_associated_terms_value` longtext NOT NULL,
  `field_associated_terms_format` varchar(255) CHARACTER SET ascii DEFAULT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_associated_terms_format` (`field_associated_terms_format`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_associated_terms.';

--
-- Dumping data for table `node__field_associated_terms`
--

INSERT INTO `node__field_associated_terms` VALUES ('indicator',0,399,408,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Doha Declaration:</span></span></span></strong></span></span><span><span><span><span><span><span> World Trade Organization adopted the TRIPS Agreement in 2001 in Doha. The Doha Declaration acknowledges the role of patents in the development of new medicines, but affirms that \"the TRIPS Agreement does not and should not prevent Members from taking measures to protect public health\". It supports the \"principles WHO has publicly advocated and advanced over the years, namely the re-affirmation of the right of WTO Members to make full use of the safeguard provisions of the TRIPS Agreement in order to protect public health and enhance access to medicines for poor countries\" (WHO, <a href=\"https://www.who.int/medicines/areas/policy/doha_declaration/en/\">https://www.who.int/medicines/areas/policy/doha_declaration/en/</a>)<br />\r\nTRIPS: Agreement on Trade Related Aspects of Intellectual Property Rights, Including Trade in Counterfeit Goods (<a href=\"https://www.wto.org/english/docs_e/legal_e/27-trips_03_e.htm\">https://www.wto.org/english/docs_e/legal_e/27-trips_03_e.htm</a>)<br />\r\nTRIPS flexibilities (paragraph 6 of the Preamble of the TRIPS Agreement):<br />\r\n“[...] the special needs of the least-developed country Members in respect of maximum flexibility in the domestic implementation of laws and regulations in order to enable them to create a sound and viable technological base.”</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,400,409,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Project deviation: </span></span></span></strong></span></span><span><span><span><span><span><span>Any non-conformity between the plan of a project&nbsp;and actual work.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,401,410,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Audit:</span></span></span></strong></span></span><span><span><span><span><span><span> An internal (conducted by the own organization)/external (conducted by third independent parties) examination of a process to add credibility to its reliability and integrity.</span></span></span></span></span></span><br />\r\n<span><strong><span><span><span>Certification: </span></span></span></strong></span><span><span><span><span><span>Tool that adds credibility to a process, product or service, demonstrating that it meets certain characteristics. There are numerous certifications available in the market for different products, processes, services and characteristics.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,402,411,'en',0,'<p><span><span><span><span><span><span><strong><span><span><span>Drug supply:</span></span></span></strong></span><span><span><span><span><span> The distribution, provision and/or sale of health care products.&nbsp;</span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,403,412,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Healthy workforce: </span></span></span></strong></span></span><span><span><span><span><span><span>Status of health of the employees that comprise a specific work systems at the organizational, local, regional, national or supranational level.</span></span></span></span></span></span><br />\r\n<span><span><span><span><span><span>&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,404,413,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Community benefit</span></span></span></strong></span></span><span><span><span><span><span><span>: The enhancement of community health outcomes as a result of research outputs (Sarli et al., 2010).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,405,414,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Economic value:</span></span></span></strong></span></span><span><span><span><span><span><span> Wealth that an organization creates for </span></span></span></span></span></span><span><span><span><span><span>stakeholders. </span></span></span></span></span><br />\r\n<span><strong><span><span><span>Revenues: </span></span></span></strong></span><span><span><span><span><span>Net sales plus income from financial investments and sales of assets.&nbsp;</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,406,415,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Return on investment:</span></span></span></strong></span><span><span><span><span><span> Percentage of the net profit of an investment compared to the cost of the investment/assets</span></span></span></span></span><span><span><span><span><span><span>.</span></span></span></span></span></span><br />\r\n<span><strong><span><span><span>Income: </span></span></span></strong></span><span><span><span><span><span>Revenue minus expenses.</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Assets: </span></span></span></strong></span></span><span><span><span><span><span><span>Elements owned by or belonging to an organization, which can be monterarily valued. An asset can be (1) something physical, such as cash, machinery, inventory, land and building, (2) an enforceable claim against others, such as accounts receivable, (3) right, such as copyright, patent, trademark, or (4) an assumption, such as goodwill.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,407,416,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Debt: </span></span></span></strong></span></span><span><span><span><span><span><span>Amount owed for funds borrowed.</span></span></span></span></span></span><br />\r\n<span><strong><span><span><span>Income:</span></span></span></strong></span><span><span><span><span><span> Revenue minus expenses.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,408,417,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Patent/intellectual property: </span></span></span></strong></span><span><span><span><span><span>The official legal right to make or sell an invention for a particular number of years (Cambridge Dictionary).</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Book value of the patent/intellectual property: </span></span></span></strong></span></span><span><span><span><span><span><span>Value that a patent has in the balance sheet of the initiative.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,409,418,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Cost-benefit analysis:</span></span></span></strong></span></span><span><span><span><span><span><span> Process by which organizations can analyze/identify the benefits of an action as well as the associated costs. The ratio is obtained by dividing the total </span></span></span></span></span></span><span><span><span><span><span>benefits by the total costs.</span></span></span></span></span><br />\r\n<span><strong><span><span><span>Health outcomes:</span></span></span></strong></span><span><span><span><span><span> Changes in health that result from specific health care interventions/programs. </span></span></span></span></span><br />\r\n<span><strong><span><span><span>Return on investment:</span></span></span></strong></span><span><span><span><span><span> Percentage of the net profit of an investment compared to the cost of the investment/assets.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,410,419,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Patent/intellectual property:</span></span></span></strong></span></span><span><span><span><span><span><span> The official legal right to make or sell an invention for a particular number of years (Cambridge </span></span></span></span></span></span><span><span><span><span><span>Dictionary).</span></span></span></span></span><br />\r\n<span><strong><span><span><span>Revenue from intellectual property: </span></span></span></strong></span><span><span><span><span><span>Income obtained from exploiting intellectual property rights.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,411,420,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,412,421,'en',0,'<p>N/A</p>\r\n','basic_html'),('indicator',0,413,422,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Stakeholder engagement: </span></span></span></strong></span></span><span><span><span><span><span><span>Activities that can be done with stakeholders: consult, listen, understand, communicate, influence, negotiate, etc., with the broader objectives of satisfying their needs, gaining approval and support, or at least minimising their opposition or obstruction (D9.1)</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,414,423,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Cost per unit: </span></span></span></strong></span></span><span><span><span><span><span><span>The production cost for each unit. Equal to total cost of production divided by the quantity of units produced.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,415,424,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Cost-effectiveness: </span></span></span></strong></span></span><span><span><span><span><span><span>Comparison between the relative costs and outcomes (effects) of health services.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,416,425,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Drug recalls</span></span></span></strong></span></span><span><span><span><span><span><span>: Removal of a defective drug product from the market.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,417,426,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Job creation:</span></span></span></strong></span></span><span><span><span><span><span><span> Process by which the number of jobs increases.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,418,427,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,419,428,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Disease:</span></span></span></strong></span></span><span><span><span><span><span><span> Any harmful deviation from the normal structural or functional state of an organism.</span></span></span></span></span></span><br />\r\n<span><strong><span><span><span>Drug supply: </span></span></span></strong></span><span><span><span><span><span>The distribution, provision and/or sale of health care products.&nbsp;</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,420,429,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Drug supply:</span></span></span></strong></span><span><span><span><span><span> The distribution, provision and/or sale of health care products. </span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Counsel: </span></span></span></strong></span></span><span><span><span><span><span><span>Advice, especially that given formally.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,421,430,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Responsible governance: </span></span></span></strong></span><span><span><span><span><span>Participatory governance model based on defining and co-designing a transformational agenda and adopting a co-accountability approach.</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Monitoring system: </span></span></span></strong></span></span><span><span><span><span><span><span>Set of mechanisms to measure how, where, and to what extent RRI has become integrated within European Research practices (D5.4).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,422,431,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Health benefits/impact: </span></span></span></strong></span></span><span><span><span><span><span><span>The positive effect of the initiative/project on health (gains, improved cost-efficiency/accessibility, qualitative improvements).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,423,432,'en',0,'<p><span><span><span><span><span><span><strong><span><span><span>Health management: </span></span></span></strong></span><span><span><span><span><span>Identification of best practices to improve care delivery and making it affordable</span></span></span></span></span><br />\r\n<span><strong><span><span><span>Population screening:</span></span></span></strong></span><span><span><span><span><span>&nbsp;T</span></span></span></span></span></span></span></span></span></span>he presumptive identification of unrecognized disease in an apparently healthy, asymptomatic population by means of tests, examinations or other procedures that can be applied rapidly and easily to the target population (WHO).</p>\r\n','basic_html'),('indicator',0,424,433,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Digital technologies:</span></span></span></strong></span></span><span><span><span><span><span><span> All types of electronic equipment and applications that use information in the form of numeric coding&nbsp;including telemedicine, web-based analysis and clinic or remote monitoring sensors.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,425,434,'en',0,'<p><span><span><span><span><span><span><strong><span><span><span>Service capacity: </span></span></span></strong></span><span><span><span><span><span>Resources and inputs in order to deal with the variety of the patient.</span></span></span></span></span><br />\r\n<span><strong><span><span><span>Disease: </span></span></span></strong></span><span><span><span><span><span>Any harmful deviation from the normal structural or functional state of an organism.</span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,426,435,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Reporting: </span></span></span></strong></span><span><span><span><span><span>Official organization\'s report about its accounts or activities (societal activities for example).</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Information transparency:</span></span></span></strong></span></span><span><span><span><span><span><span>&nbsp; Openly available and comprehensive information.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,427,436,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Gender issues: </span></span></span></strong></span></span><span><span><span><span><span><span>Concerns related to reaching the equal value and treatment between women and men.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,428,437,'en',0,'<p><span><span><span><span><span><span><strong><span><span><span>Multi-disciplinary approach:</span></span></span></strong></span><span><span><span><span><span> Process by which an issue is analyzed and studied by combining expertise of individual from different areas and backgrounds, such as scientists, biologists, </span></span></span></span></span><span><span><span><span><span>patients, govermental agencies, etc.</span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,429,438,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Professional training: </span></span></span></strong></span><span><span><span><span><span>The improvement of&nbsp; performance and methods that could be used to analyse and improve health care quality by the means of courses, workshops and training related to specific projects.</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Human capital: </span></span></span></strong></span></span><span><span><span><span><span><span>Organizations\' employees and all of the knowledge, skills, experience.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,430,439,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Clinical academic: </span></span></span></strong></span></span><span><span><span><span><span><span>Doctors who also combine research/teaching responsibilities.</span></span></span></span></span></span><br />\r\n<span><strong><span><span><span>Human capital: </span></span></span></strong><span><span><span><span>The knowledge, skills and experience of an organization\'s employees.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,431,440,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Health care service</span></span></span></strong></span></span><span><span><span><span><span><span>: Any furnishing of treatment or health </span></span></span></span></span></span><span><span><span><span><span>services.</span></span></span></span></span><br />\r\n<span><strong><span><span><span>Quality improvement:&nbsp;</span></span></span></strong></span><span><span><span><span><span>Increase&nbsp;of&nbsp;the level at which care is delivered to patients.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,432,441,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Risk stratification:</span></span></span></strong></span><span><span><span><span><span> Identification and prediction of patients that are at high risks (or likely to be at high risks) and to prioritize the management of their care in order to prevent worse outcomes.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,433,442,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Hospital admission:</span></span></span></strong></span><span><span><span><span><span> Two types of admissions can be differentiated: (1) emergent admission happens when a patient is subsequently admitted to the hospital; and (2) elective admissions happens when a&nbsp; a patient is admitted on a specific day.</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Disease management: </span></span></span></strong></span></span><span><span><span><span><span><span>A set of healthcare interventions and communications to manage a specific disease.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,434,443,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Safety plan: </span></span></span></strong></span><span><span><span><span><span>Document describing the health and safety matters in the work environment i.e, the measures to be taken&nbsp; as well as any other prerequisite to be applied to improve working conditions and to avoid work accidents and diseases.</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Physical and health hazards:</span></span></span></strong></span></span><span><span><span><span><span><span> (1) physical hazard is an agent, factor or circumstance that can cause harm with or without contact and (2) health hazard includes chemicals or toxic agents.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,435,444,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Clinical guidelines: </span></span></span></strong></span></span><span><span><span><span><span><span>Statements that include recommendations, intended to optimize patient care, that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options (Institute of Medicine, 1990).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,436,445,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Quality-adjusted life method</span></span></span></strong></span><span><span><span><span><span>: Method to calculate an economic indicator estimating the value of life.</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Health outcomes:</span></span></span></strong></span></span><span><span><span><span><span><span> Changes in health that result from specific health care interventions/programs.&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,437,446,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Mortality rate: </span></span></span></strong></span></span><span><span><span><span><span><span>The number of deaths in a given area or period respect to the whole population.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,438,447,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Life expectancy: </span></span></span></strong></span></span><span><span><span><span><span><span>Average period that patients may be expected to live.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,439,448,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Patient experience</span></span></span></strong></span></span><span><span><span><span><span><span>: The range of interactions of patients with the health care system.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,440,449,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Health promotion: </span></span></span></strong></span></span><span><span><span><span><span><span>Process that enables actors to increase control over their own health including action to address social determinants and health inequity (see Ottawa Charter for Health Promotion and <a href=\"http://chrodis.eu/\">http://chrodis.eu/</a>).</span></span></span></span></span></span><br />\r\n<span><strong><span><span><span>Stakeholder engagement: </span></span></span></strong></span><span><span><span><span><span>Activities that can be done with stakeholders: consult, listen, understand, communicate, influence, negotiate, etc., with the broader objectives of satisfying their needs, gaining approval and support, or at least minimising their opposition or obstruction (D9.1)</span></span></span></span></span></span></span></span></span></span></span><br />\r\n&nbsp;</p>\r\n','basic_html'),('indicator',0,441,450,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Patient engagement:</span></span></span></strong></span></span><span><span><span><span><span><span> Action to engage patients in R&amp;I processes for make them responsible (as a sub-group of stakeholders). In line with RRI definition, patient engagement implies that patients work together to other stakeholders (researchers, citizens, policy makers, business, third sector organizations, etc.)&nbsp;during the whole R&amp;I process in order to better align both the process and its outcomes with the values, needs and expectations of patients.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,442,451,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Peer-reviewed publications:</span></span></span></strong></span><span><span><span><span><span> Academic articles that have been peer-reviewed for their publications.</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>High-impact journals:</span></span></span></strong></span></span><span><span><span><span><span><span> Journal that are listed in the top quartile of a journal ranking. As a rule of thumb, high-impact journal are those in the top 10% of a ranking.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,443,452,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,444,453,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Open access:</span></span></span></strong></span><span><span><span><span><span> Idea of making research results freely available to anyone who wants to access and re-use them (e.g. for full text mining) (MoRRI).</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Gold open access:</span></span></span></strong></span></span><span><span><span><span><span><span>&nbsp;Publications in OA journals (MoRRI).</span></span></span></span></span></span><br />\r\n<span><strong><span><span><span>Green open access</span></span></span></strong></span><span><span><span><span><span>: Publications in OA self-archiving databases (MoRRI).</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,445,454,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Anticipatory design: </span></span></span></strong></span></span><span><span><span><span><span><span>The design of products and services by using foresight techniques. Foresight techniques are coming </span></span></span></span></span></span><span><span><span><span><span>and that is why the impact of anticipatory design needs to be thoroughly understood (Yaghmaei, 2018).</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,446,455,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,447,456,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,448,457,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,449,458,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Outreach activities: </span></span></span></strong></span></span><span><span><span><span><span><span>Activities by research institutions that seek to increase public awareness and understanding of scienctific knowledge and contribute to informal science education. </span></span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Refereed publications: </span></span></span></strong></span></span><span><span><span><span><span><span>Academic articles that have been peer-reviewed for their publications.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,450,459,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Media:</span></span></span></strong></span></span><span><span><span><span><span><span> Mediums of massive information dissemination (e.g., press releases, contacts, articles).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,451,460,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,452,461,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Clinical guidelines: </span></span></span></strong></span></span><span><span><span><span><span><span>&nbsp;Statements that include recommendations, intended to optimize patient care, that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options (Institute of Medicine, 1990).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,453,462,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Risk</span></span></span></strong></span></span><span><span><span><span><span><span>: Future uncertainty about deviation from expected outcomes.&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,454,463,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Code of ethics/Code of conduct:</span></span></span></strong></span></span><span><span><span><span><span><span> A statement setting down corporate principles, ethics, rules of conduct, codes of practice or company philosophy concerning responsibility to employees, shareholders, consumers, the environment, or any other aspects of society external to the company (Langlois and Schlegelmilch, 1990, p. 522).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,455,464,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Code of ethics/Code of conduct:</span></span></span></strong></span></span><span><span><span><span><span><span> A statement setting down corporate principles, ethics, rules of conduct, codes of practice or company philosophy concerning responsibility to employees, shareholders, consumers, the environment, or any other aspects of society external to the company (Langlois and Schlegelmilch, 1990, p. 522).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,456,465,'en',0,'<p><span><span><span><span>N/A</span></span></span></span></p>\r\n','basic_html'),('indicator',0,457,466,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Research grants:</span></span></span></strong></span></span><span><span><span><span><span><span> Non-repayable funds obtained from funding organizations to carry out research studies.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,458,467,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Collaborative research: </span></span></span></strong></span></span><span><span><span><span><span><span>Research developed by a&nbsp;partnership between two or more&nbsp;members who are pursuing mutually interesting research.&nbsp;Collaborative research represents the core of EU R&amp;I funding under Horizon 2020 with a multitude of funding options, thematic priorities with a variable degree of specification, regular collaboration of science and industry/society, different governance models for funding, (https://www.kowi.de/en/kowi/collaborative-research/collaborative-research.aspx).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,459,468,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Public involvement/engagement: </span></span></span></strong></span></span><span><span><span><span><span><span>The inclusion and consideration of the general public as a key stakeholder in the decision-making process to plan, manage and carry out research.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,460,469,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Taxonomy: </span></span></span></strong></span><span><span><span><span><span>System for naming and organizing diseases.</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Disease:</span></span></span></strong></span></span><span><span><span><span><span><span> Any harmful deviation from the normal structural or functional state of an organism.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,461,470,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>The science of patient input:</span></span></span></strong></span></span><span><span><span><span><span><span> Scientific discipline aimed at understanding and incorporating patient needs and perspectives into the processes of governing and sustaining health research, developing, regulating, and delivering new therapies as well as improving care (see D1.1).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,462,471,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Social impact:</span></span></span></strong></span></span><span><span><span><span><span><span> The effect on the well being of the society.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,463,472,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Expected / targeted changes:</span></span></span></strong></span></span><span><span><span><span><span><span> Milat et al. (2013) follow Banzi et al. (2011) to differentiate five broad categories of research impacts: i) advancing knowledge; ii) capacity building; iii) informing decision-making; iv) health benefits; and, v) broad socio-economic benefits.<br />\r\nMilat et al. (2013) found that knowledge generated through research projects can inform practice and lead to changes through: Informing organizational development, leading to new intervention tool and resources, informing professional development, health promotion and programs.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,464,473,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,465,474,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,466,475,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,467,476,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Knowledge translation: </span></span></span></strong><span><span><span>The exchange and application of knowledge within interactions between different actors. It allows the development of research through improved health and a strengthened health care&nbsp;system.</span></span></span><br />\r\n<strong><span><span><span>Informing practice: </span></span></span></strong><span><span><span>Provide practioners with facts or information that is useful for developing their tasks.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,468,477,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,469,478,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,470,479,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Patent/intellectual property: </span></span></span></strong></span></span><span><span><span><span><span><span>The official legal right to make or sell an invention for a particular number of years (Cambridge Dictionary).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,471,480,'en',0,'<p><span><span><span><span><span><span><strong><span><span><span>Patent/intellectual property: </span></span></span></strong></span><span><span><span><span><span>The official legal right to make or sell an invention for a particular number of years (Cambridge Dictionary).</span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,472,481,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Patent/intellectual property: </span></span></span></strong></span><span><span><span><span><span>The official legal right to make or sell an invention for a particular number of years (Cambridge Dictionary).</span></span></span></span></span><br />\r\n<span><strong><span><span><span>Produced patents: </span></span></span></strong></span><span><span><span><span><span>Patents that the initiatives produced. They can be commercialized or not.</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Commercialized patents</span></span></span></strong></span></span><span><span><span><span><span><span>: Patents that the research initiative manages or exploites to make a profit.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,473,482,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Clinical trials phases:</span></span></span></strong></span></span><span><span><span><span><span><span> Phase I (pharmacology studies); phase II (therapeutic exploratory investigations); phase III (assessments of the effectiveness of the new intervention); and phase IV (investigations into uncommon adverse effects of the new intervention).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,474,483,'en',0,'<p><span><strong><span><span><span><span>Public involvement/engagement: </span></span></span></span></strong><span><span><span><span><span><span><span><span><span><span>The inclusion and consideration of the general public as a key stakeholder in the decision-making process to plan, manage and carry out research.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,475,484,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Drug: </span></span></span></strong></span></span><span><span><span><span><span><span>Natural or synthetic substance which (when taken into a living body) affects its functioning or structure, and is used in the diagnosis, mitigation, treatment, or prevention of a disease or relief of discomfort (www.businessdictionary.com).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,476,485,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Therapeutic advance: </span></span></span></strong></span></span><span><span><span><span><span><span>Treatment and care of a patient for the purpose of both preventing and combating disease or alleviating pain or injury (Encyclopedia Britannica).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,477,486,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Spin-off:</span></span></span></strong></span></span><span><span><span><span><span><span> New business created by separating part of a company (Cambridge Dictionary).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,478,487,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Drug:</span></span></span></strong></span></span><span><span><span><span><span><span> Natural or synthetic substance which (when taken into a living body) affects its functioning or structure, and is used in t</span></span></span></span></span></span><span><span><span><span><span>he diagnosis, mitigation, treatment, or prevention of a disease or relief of discomfort (www.businessdictionary.com).</span></span></span></span></span><br />\r\n<span><strong><span><span><span>Therapeutic advance: </span></span></span></strong></span><span><span><span><span><span>Treatment and care of a patient for the purpose of both preventing and combating disease or alleviating pain or injury (Encyclopedia Britannica).</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,479,488,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Partnerships:</span></span></span></strong></span></span><span><span><span><span><span><span> Relationship formed by the agreement between two or more organizations to carry on research and development of new products and services together.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,480,489,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Patient engagement: </span></span></span></strong></span></span><span><span><span><span><span><span>Action to engage patients in R&amp;I processes for make them responsible (as sub-group of stakeholder). In line with RRI definition, patient engagement implies that patients work together with&nbsp;other stakeholders (researchers, citizens, policy makers, business, third sector organizations, etc.)&nbsp; during the whole R&amp;I process in order to better align both the process and its outcomes with the values, needs and expectations of patients.</span></span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Stakeholder engagement: </span></span></span></strong></span></span><span><span><span><span><span><span>&nbsp;Activities that can be done with stakeholders: consult, listen, understand, communicate, influence, negotiate, etc., with the broader objectives of satisfying their needs, gaining approval and support, or at least minimizing their opposition or obstruction (D9.1).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,481,490,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Funding applications:</span></span></span></strong></span></span><span><span><span><span><span><span> The process of elaborating, writing and proposing a&nbsp; request for the financing of a project.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n\r\n<p><strong>Translational&nbsp;funding: </strong>Funding&nbsp;used to ‘bridge the gap’ in development between early stage technology resulting from research&nbsp;and its commercialization.</p>\r\n','basic_html'),('indicator',0,482,491,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Leadership:</span></span></span></strong></span></span><span><span><span><span><span><span> The influence&nbsp; and impact of the research awareness (e.g.&nbsp;number and type of public recognitions, number of editorial board served and number of research bodies).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,483,492,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,484,493,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Capacity development:</span></span></span></strong></span></span><span><span><span><span><span><span> Improvement of skills, knowledge and </span></span></span></span></span></span><span><span><span><span><span>resources required to do research.</span></span></span></span></span><br />\r\n<span><strong><span><span><span>Training program:</span></span></span></strong></span><span><span><span><span><span> Set of activities that contribute to improving health care research and practice by means of courses, workshops and mentoring.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,485,494,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Human capital:</span></span></span></strong><span><span><span><span>&nbsp;The&nbsp;knowledge, skills and&nbsp;experience of an organization\'s employees.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,486,495,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Gender issues:</span></span></span></strong></span></span><span><span><span><span><span><span> Concerns related to reaching the equal value and treatment between women and men.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,487,496,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Gender issues:</span></span></span></strong></span></span><span><span><span><span><span><span> Concerns related to reaching the equal value and treatment between women and men.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,488,497,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>R&amp;D investments: </span></span></span></strong></span><span><span><span><span><span>Innovative and financial investments devoted to research.</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Disease:</span></span></span></strong></span></span><span><span><span><span><span><span> Any harmful deviation from the normal structural or functional state of an organism.</span></span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Resource allocation: </span></span></span></strong></span></span><span><span><span><span><span><span>Assignment of available resources to various uses.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,489,498,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Research strategy:</span></span></span></strong></span></span> <span><span><span><span><span><span>Definition of the actions that should be carried out to achieve the research objectives that have been defined.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,490,499,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Knowled</span></span></span></strong></span></span><span><strong><span><span><span>ge work: </span></span></span></strong></span><span><span><span><span><span>&nbsp;Work performed by someone with specific domain knowledge who specializes in separating relevant information from irrelevant information.</span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,491,500,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Gorvernance: </span></span></span></strong></span></span><span><span><span><span><span><span>Internal structure and decision-making scheme of a research initiative, which will enable the appropriate management of project activities in the long run (D5.1)</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,492,501,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Stakeholder engagement</span></span></span></strong></span></span><span><span><span><span><span><span>:&nbsp; Activities that can be done with stakeholders: consult, listen, understand, communicate, influence, negotiate, etc., with the broader objectives of satisfying their needs, gaining approval and support, or at least minimising their opposition or obstruction (D9.1).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,493,502,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Research methodology</span></span></span></strong></span></span><span><span><span><span><span><span>: Specific techniques adopted in research processes to collect, assemble and evaluate data.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,494,503,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Stakeholder engagement: </span></span></span></strong></span></span><span><span><span><span><span><span>&nbsp;</span></span></span></span></span></span><span><span><span><span><span><span>Activities that can be done with stakeholders: consult, listen, understand, communicate, influence, negotiate, etc., with the broader objectives of satisfying their needs, gaining approval and support, or at least minimising their opposition or obstruction (D9.1).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,495,504,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>External stakeholder:</span></span></span></strong></span></span><span><span><span><span><span><span>&nbsp; Individuals or groups that are outside the initiative/project’s environment, have some interest in the initiative/project\'s aims and might influence to different extents its execution and the accomplishment of its expected results.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,496,505,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Stakeholder engagement:</span></span></span></strong></span></span><span><span><span><span><span><span> Activities that can be done with stakeholders: consult, listen, understand, communicate, influence, negotiate, etc., with the broader objectives of satisfying their needs, gaining approval and support, or at least minimising their opposition or obstruction (D9.1).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,497,506,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,498,507,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Ethical marketing</span></span></span></strong></span><span><span><span><span><span>: The systematic study of how moral standards are applied to marketing decisions, behaviours and institutions (Murphy et al., 2005, p. 17).</span></span></span></span></span><br />\r\n<span><strong><span><span><span>Corruption</span></span></span></strong></span><span><span><span><span><span>: The abuse of entrusted power for private gain (Transparency International).</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Code of ethics/Code of conduct</span></span></span></strong></span></span><span><span><span><span><span><span>: A statement setting down corporate principles, ethics, rules of conduct, codes of practice or company philosophy concerning responsibility to employees, shareholders, consumers, the environment, or any other aspects of society external to the company (Langlois and Schlegelmilch, 1990, p. 522).</span></span></span></span></span></span><br />\r\n<span><strong><span><span><span>Enforcement procedures</span></span></span></strong></span><span><span><span><span><span>: Mechanisms and sanctions established to </span></span></span></span></span><span><span><span><span><span><span>guarantee the effective application of the code of ethics and deal with potential violations. </span></span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Risk</span></span></span></strong></span></span><span><span><span><span><span><span>: Future uncertainty about deviation from expected outcome.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,499,508,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Working conditions: </span></span></span></strong></span></span><span><span><span><span><span><span>Conditions in which employees work, including degree of safety or danger.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,500,509,'en',0,'<p><span><span><span><span><span><span>N/A</span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,501,510,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Employee turnover: </span></span></span></strong><span><span><span>P</span></span></span></span></span><span><span><span><span><span><span>ercentage of workers who leave an organization and are replaced by new employees.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,502,511,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Training program:</span></span></span></strong></span></span><span><span><span><span><span><span> Set of activities that contribute to improving health care research and practice by the means of courses, workshops and mentoring.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,503,512,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Expected / targeted changes:</span></span></span></strong></span></span><span><span><span><span><span><span> Milat et al. (2013) follow Banzi et al. (2011) to differentiate five broad categories of research impacts: i) advancing knowledge; ii) capacity building; iii) informing decision-making; iv) health benefits; and, v) broad socio-economic benefits.<br />\r\nMilat et al. (2013) found that knowledge generated through research projects can inform practice and lead to changes through: Informing organizational development, leading to new intervention tool and resources, informing professional development, health promotion and programs.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,504,513,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Gorvernance:</span></span></span></strong></span></span><span><span><span><span><span><span> Internal structure and decision-making scheme of a research initiative, which will enable the appropriate management of project activities in the long run (D5.1).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,505,514,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>External stakeholder:</span></span></span></strong></span></span><span><span><span><span><span><span>&nbsp; Individuals or groups that are outside the organization’s environment, have some interest in the initiative\'s aims and might influence to different extents its execution and the accomplishment of its expected results. Government agencies are a type of external stakeholders.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,506,515,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Environmental audit:</span></span></span></strong></span></span><span><span><span><span><span><span> External (conducted by third independent parties) examination of a process to add credibility to its reliability and integrity.</span></span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Environmental management/compliance:</span></span></span></strong></span></span><span><span><span><span><span><span> Conforming to environmental laws, regulations and standards.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,507,516,'en',0,'<p><span><span><span><span><span><span><span><strong><span><span><span>Sustainable product manufacturing: </span></span></span></strong></span><span><span><span><span><span>Creation of healthcare products through economically-sound processes (i.e.&nbsp;with few negative environmental impacts).</span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Raw material:</span></span></span></strong></span></span><span><span><span><span><span><span> Materials or substances used in the primary production or manufacturing of products (e.g.&nbsp;the excipients or the components).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,508,517,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Greenhouse gas (GHG):</span></span></span></strong></span></span><span><span><span><span><span><span> Any of various gaseous compounds (carbon dioxide for example) that trap heat or longwave radiation in the atmosphere and contribute to the greenhouse effect.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,509,518,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Community involvement/engagement: </span></span></span></strong></span></span><span><span><span><span><span><span>The inclusion and consideration of communities as a key stakeholder in the decision-making process to plan, manage and carry out research.</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,510,519,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>Public/community involvement/engagement: </span></span></span></strong></span></span><span><span><span><span><span><span>The inclusion and consideration of communities as a key stakeholder in the decision-making process to plan, manage and carry out research.</span></span></span></span></span></span><br />\r\n<span><span><strong><span><span><span>Stakeholders engagement:</span></span></span></strong></span></span><span><span><span><span><span><span> Activities that can be done with stakeholders: consult, listen, understand, communicate, influence, negotiate, etc., with the broader objectives of satisfying their needs, gaining approval and support, or at least minimizing their opposition or obstruction (D9.1).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,512,521,'en',0,'<p><span><span><span><span><span><span><span><span><strong><span><span><span>RRI: </span></span></span></strong></span></span><span><span><span><span><span><span>Responsible research and innovation is an approach that anticipates and assesses potential implications and societal expectations with regard to research and innovation, with the aim to foster the design of inclusive and sustainable research and innovation (EU-Horizon 2020).</span></span></span></span></span></span></span></span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,547,557,'en',0,'<p><span><span><span><strong><span><span>Patients engagement: </span></span></strong><span><span>Actions to engage patients in R&amp;I processes for make them responsible (as sub-group of stakeholder). In line with RRI definition, patient engagement implies that patients work together with&nbsp;other stakeholders (researchers, citizens, policy makers, business, third sector organizations, etc.)&nbsp; during the whole R&amp;I process in order to better align both the process and its outcomes with the values, needs and expectations of patients.</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,548,558,'en',0,'<p><span><span><span><span><span>N/A</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,549,559,'en',0,'<p><span><span><span><strong><span><span>Patient Reported Outcomes</span></span></strong><span><span>: Report on how patients feel or function</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,550,560,'en',0,'<p><span><span><span><strong><span><span>Patient Reported Outcomes</span></span></strong><span><span>: Report on how patients feel or function</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,551,561,'en',0,'<p><span><span><span><strong><span><span>Patient Reported Outcomes</span></span></strong><span><span>: Report on how patients feel or function</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,552,562,'en',0,'<p><span><span><span><strong><span><span>Patient Reported Outcomes</span></span></strong><span><span>: Report on how patients feel or function</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,553,563,'en',0,'<p><span><span><span><strong><span><span>Patient Reported Outcomes</span></span></strong><span><span>: Report on how patients feel or function</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,554,564,'en',0,'<p><span><span><span><strong><span><span>Patient Reported Outcomes</span></span></strong><span><span>: Report on how patients feel or function</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,585,612,'en',0,'<p>Patient Reported Outcomes: Report on how patients feel or function<br />\r\n&nbsp;</p>\r\n','basic_html');

--
-- Table structure for table `node__field_comments`
--

CREATE TABLE `node__field_comments` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_comments_value` longtext NOT NULL,
  `field_comments_format` varchar(255) CHARACTER SET ascii DEFAULT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_comments_format` (`field_comments_format`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_comments.';

--
-- Dumping data for table `node__field_comments`
--

INSERT INTO `node__field_comments` VALUES ('indicator',0,401,410,'en',0,'<p>Certifications could be used as a proxy.</p>\r\n','basic_html'),('indicator',0,406,415,'en',0,'<p>Ideally, an initiative/project&nbsp;should provide the ROI specific for health research. Given the complexity of its calculation, it can opt for the general ROI if the first option is too demanding.</p>\r\n','basic_html'),('indicator',0,407,416,'en',0,'<p>Process to calculate it considering the information provided in financial statements. For instance, in the&nbsp;Burnet Institute 2018 Financial Report,&nbsp;divide \"total liabilities\" (p. 10) by \"results from operating activity\" (p. 9) times 100.</p>\r\n\r\n<p>The&nbsp;Burnet Institute 2018 Financial Report is available at:&nbsp;<a href=\"https://www.burnet.edu.au/system/annual_report/file/25/Financial_Report_2018_-_digital.pdf\">https://www.burnet.edu.au/system/annual_report/file/25/Financial_Report_2018_-_digital.pdf</a></p>\r\n','basic_html'),('indicator',0,408,417,'en',0,'<p>Process to calculate it considering the information provided in financial statements. For instance, in&nbsp;Sanofi 2018 Annual Report,&nbsp;divide \"other intangible assets\" (see note D.35.3 - page F111) by \"carrying amount of products, trademarks and other rights\" (see note D.4 - page F44). Sanofi 2018 Annual Report is available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Sanofi-20-F-2018-EN-PDF-e-accessible_02.pdf?la=en&amp;hash=0E0CB0122FEDA3881B3857221DB9345A\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/Sanofi-20-F-2018-EN-PDF-e-accessible_02.pdf?la=en&amp;hash=0E0CB0122FEDA3881B3857221DB9345A</a></p>\r\n\r\n<p>If the indicator is difficult to calculate to some initiatives/projects, it could be simplified by dividing the revenues obtained from the exploitation of patents and intellectual property rights by the total number of patents/intellectual property rights owned by the initiative/project.</p>\r\n','basic_html'),('indicator',0,409,418,'en',0,'<p>The data can&nbsp;be provided in a graphic, like in the example.</p>\r\n','basic_html'),('indicator',0,410,419,'en',0,'<p>This indicator can be used to compute the indicator \"return on intellectual property\".</p>\r\n','basic_html'),('indicator',0,412,421,'en',0,'<p>The example only provide the number of new products developed during the reporting period.</p>\r\n','basic_html'),('indicator',0,414,423,'en',0,'<p>The indicator must be tested and adjusted through a regular, double-feedback-loop process (Kaplan &amp; Norton, 2006), which analyses the differences between what was foreseen and the actual results and accordingly changes the model and the strategic assumptions at the basis of its construction.</p>\r\n','basic_html'),('indicator',0,417,426,'en',0,'<p>The example does not disaggregate the number of jobs created by gender.</p>\r\n','basic_html'),('indicator',0,419,428,'en',0,'<p>The indicator can also be provided in a graphic, like in the example.</p>\r\n','basic_html'),('indicator',0,425,434,'en',0,'<p>Additional information:&nbsp;Hogan, D. R., Stevens, G. A., Hosseinpoor, A. R., &amp; Boerma, T. (2018). Monitoring universal health coverage within the Sustainable Development Goals: development and baseline data for an index of essential health services.&nbsp;<em>The Lancet Global Health</em>,&nbsp;<em>6</em>(2), e152-e168.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(17)30472-2/fulltext\">https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(17)30472-2/fulltext</a></p>\r\n','basic_html'),('indicator',0,426,435,'en',0,'<p>Companies should track progress in access-to-medicine outcomes against defined goals, conduct impact assessments of access activities and make results publicly available</p>\r\n','basic_html'),('indicator',0,429,438,'en',0,'<p>The example lists the training courses. It is possible to compute the number by counting the training courses provided.</p>\r\n','basic_html'),('indicator',0,430,439,'en',0,'<p>The example provide the information as a percentage. The number can be calculate by applying the percentage to the total number of employees reported in the same page.&nbsp;The indicator&nbsp;does not disaggregate the number of employed academics by gender.</p>\r\n','basic_html'),('indicator',0,432,441,'en',0,'<p>For how to develop a predictive risk model, see the guide \"A risk stratification tool for hospitalisation in Australia using primary care data\". Available at:&nbsp;<a href=\"https://www.nature.com/articles/s41598-019-41383-y\">https://www.nature.com/articles/s41598-019-41383-y</a><br />\r\nFor how to compute the indicator, see Sigakis et al. (2013): \"Validation of a Risk Stratification Index and Risk Quantification Index for Predicting Patient Outcomes\". Available at:&nbsp;<a href=\"https://anesthesiology.pubs.asahq.org/article.aspx?articleid=1918181\">https://anesthesiology.pubs.asahq.org/article.aspx?articleid=1918181</a></p>\r\n\r\n<p>Data can also be provided graphically (see example).</p>\r\n','basic_html'),('indicator',0,436,445,'en',0,'<p>Full paper of Prieto &amp; Sacristán on computing QALYs is available at: <a href=\"https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-1-80\">https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-1-80</a></p>\r\n','basic_html'),('indicator',0,442,451,'en',0,'<p>Use the Journal Citation Report Impact Factor as benchmark to categorize journal as high-impact. Otherwise, the initiative should clearly indicate if a different ranking is used for the sake of comparability.</p>\r\n','basic_html'),('indicator',0,444,453,'en',0,'<p>The example provided is not specific of health research initiatives, but it can be adapted to their scope.</p>\r\n','basic_html'),('indicator',0,446,455,'en',0,'<p>Adopt Google Scholar as a reference for academic citations to make the indicator more comparable among different initiatives</p>\r\n','basic_html'),('indicator',0,456,465,'en',0,'<p>More information on the indicator is available in MoRRI – The Evolution and Benefits of Responsible Research and Innovation (p. 74).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1\">https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1</a></p>\r\n','basic_html'),('indicator',0,466,475,'en',0,'<p>Those initiatives/project&nbsp;that have not a a shared strategy yet can develop one, and those that already have one should update its strategy so that it is&nbsp;aligned with the scientific priorities as defined in the project/initiative\'s Research Strategy.</p>\r\n','basic_html'),('indicator',0,470,479,'en',0,'<p>This indicator provides additional information to the indicator \"Revenue from intellectual property\".</p>\r\n','basic_html'),('indicator',0,472,481,'en',0,'<p>Link to the World Intellectual Property Organization Database:&nbsp;<a href=\"https://www.wipo.int/branddb/en/\">https://www.wipo.int/branddb/en/</a></p>\r\n\r\n<p>The tabulated data can also be presented as a graphic.<br />\r\nThis indicator can be used to compute the indicator \"return on intellectual property\".</p>\r\n','basic_html'),('indicator',0,478,487,'en',0,'<p>This indicator complement the information provided by indicators \"New products\" and \"Therapeutic advances\".</p>\r\n','basic_html'),('indicator',0,481,490,'en',0,'<p>The example provides additional information on consortia members and not the number of consortia.</p>\r\n','basic_html'),('indicator',0,483,492,'en',0,'<p>See AIHS health research&nbsp;impact framework (Graham et al., 2012).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://academic.oup.com/rev/article-abstract/21/5/354/1559212\">https://academic.oup.com/rev/article-abstract/21/5/354/1559212</a></p>\r\n','basic_html'),('indicator',0,484,493,'en',0,'<p>The example does not disaggregate the number by gender.</p>\r\n','basic_html'),('indicator',0,491,500,'en',0,'<p>Consider the relationship with the Governance Model established in Multi-Act.</p>\r\n\r\n<p>Normally this&nbsp;information is&nbsp;available on the website of the organization/project and in its statutes.</p>\r\n','basic_html'),('indicator',0,494,503,'en',0,'<p>The example is overwhelming; usually the indicator could just consist in one table. Also, it does not present stakeholders per category. &nbsp;</p>\r\n','basic_html'),('indicator',0,503,512,'en',0,'<p>In reserch organizations, this information is often implicit. Indicators 66 &amp; 107 provide complementary perspectives.</p>\r\n','basic_html'),('indicator',0,504,513,'en',0,'<p>More information in how to compute the indicators in&nbsp;MoRRI – Monitoring the Evolution and Benefits of Responsible Research and Innovation (see pp. 77-81).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1/language-en\">https://op.europa.eu/en/publication-detail/-/publication/2c5a0fb6-c070-11e8-9893-01aa75ed71a1/language-en</a></p>\r\n','basic_html'),('indicator',0,505,514,'en',0,'<p>This information is often embedded in the general section about stakeholder engagement (see example). If that is the case, the initiative can refer to that section.</p>\r\n','basic_html'),('indicator',0,551,561,'en',0,'<p><span><span><span><span><span>Indicators disease-specific (MS)</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,552,562,'en',0,'<p><span><span><span><span><span>Indicators disease-specific (MS)</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,585,612,'en',0,'<p>Indicators disease-specific (MS)</p>\r\n','basic_html');

--
-- Table structure for table `node__field_core_activities`
--

CREATE TABLE `node__field_core_activities` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_core_activities_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_core_activities_value` (`field_core_activities_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_core_activities.';

--
-- Dumping data for table `node__field_core_activities`
--

INSERT INTO `node__field_core_activities` VALUES ('initiative',0,309,318,'en',0,'Community care research'),('initiative',0,309,318,'en',1,'Detection, screening and diagnosis'),('initiative',0,310,319,'en',0,'Detection, screening and diagnosis'),('initiative',0,516,525,'en',0,'Health and social care services research'),('initiative',0,518,528,'en',0,'Community care research'),('initiative',0,519,529,'en',0,'Community care research'),('initiative',0,520,530,'en',0,'Detection, screening and diagnosis'),('initiative',0,521,531,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,522,532,'en',0,'Digital transformation of health sector'),('initiative',0,523,533,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,524,534,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,525,535,'en',0,'Detection, screening and diagnosis'),('initiative',0,526,536,'en',0,'Community care research'),('initiative',0,527,537,'en',0,'Community care research'),('initiative',0,528,538,'en',0,'Community care research'),('initiative',0,529,539,'en',0,'Detection, screening and diagnosis'),('initiative',0,529,539,'en',1,'Digital transformation of health sector'),('initiative',0,530,540,'en',0,'Detection, screening and diagnosis'),('initiative',0,530,540,'en',1,'Digital transformation of health sector'),('initiative',0,530,540,'en',2,'Health and social care services research'),('initiative',0,530,540,'en',3,'Prevention of diseases and conditions / promotion of health and wellbeing'),('initiative',0,531,541,'en',0,'Detection, screening and diagnosis'),('initiative',0,531,541,'en',1,'Development of treatments and therapeutic interventions'),('initiative',0,534,544,'en',0,'Prevention of diseases and conditions / promotion of health and wellbeing'),('initiative',0,535,545,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,536,546,'en',0,'Health and social care services research'),('initiative',0,537,547,'en',0,'Community care research'),('initiative',0,538,548,'en',0,'Underpinning research and aetiology'),('initiative',0,539,549,'en',0,'Underpinning research and aetiology'),('initiative',0,540,550,'en',0,'Management of diseases and conditions'),('initiative',0,541,551,'en',0,'Digital transformation of health sector'),('initiative',0,542,552,'en',0,'Prevention of diseases and conditions / promotion of health and wellbeing'),('initiative',0,543,553,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,544,554,'en',0,'Community care research'),('initiative',0,544,554,'en',1,'Detection, screening and diagnosis'),('initiative',0,545,555,'en',0,'Digital transformation of health sector'),('initiative',0,555,565,'en',0,'Community care research'),('initiative',0,555,565,'en',1,'Detection, screening and diagnosis'),('initiative',0,556,566,'en',0,'Management of diseases and conditions'),('initiative',0,557,567,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,589,616,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,590,617,'en',0,'Community care research'),('initiative',0,592,621,'en',0,'Development of treatments and therapeutic interventions'),('initiative',0,593,622,'en',0,'Underpinning research and aetiology');

--
-- Table structure for table `node__field_core_additional`
--

CREATE TABLE `node__field_core_additional` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_core_additional_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_core_additional_value` (`field_core_additional_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_core_additional.';

--
-- Dumping data for table `node__field_core_additional`
--

INSERT INTO `node__field_core_additional` VALUES ('indicator',0,399,408,'en',0,'Core'),('indicator',0,400,409,'en',0,'Core'),('indicator',0,401,410,'en',0,'Additional'),('indicator',0,402,411,'en',0,'Core'),('indicator',0,403,412,'en',0,'Additional'),('indicator',0,404,413,'en',0,'Additional'),('indicator',0,405,414,'en',0,'Additional'),('indicator',0,406,415,'en',0,'Core'),('indicator',0,407,416,'en',0,'Additional'),('indicator',0,408,417,'en',0,'Additional'),('indicator',0,409,418,'en',0,'Core'),('indicator',0,410,419,'en',0,'Core'),('indicator',0,411,420,'en',0,'Core'),('indicator',0,412,421,'en',0,'Additional'),('indicator',0,413,422,'en',0,'Additional'),('indicator',0,414,423,'en',0,'Core'),('indicator',0,415,424,'en',0,'Additional'),('indicator',0,416,425,'en',0,'Additional'),('indicator',0,417,426,'en',0,'Core'),('indicator',0,418,427,'en',0,'Additional'),('indicator',0,419,428,'en',0,'Core'),('indicator',0,420,429,'en',0,'Additional'),('indicator',0,421,430,'en',0,'Core'),('indicator',0,422,431,'en',0,'Core'),('indicator',0,423,432,'en',0,'Additional'),('indicator',0,424,433,'en',0,'Additional'),('indicator',0,425,434,'en',0,'Core'),('indicator',0,426,435,'en',0,'Additional'),('indicator',0,427,436,'en',0,'Additional'),('indicator',0,428,437,'en',0,'Core'),('indicator',0,429,438,'en',0,'Additional'),('indicator',0,430,439,'en',0,'Additional'),('indicator',0,431,440,'en',0,'Core'),('indicator',0,432,441,'en',0,'Additional'),('indicator',0,433,442,'en',0,'Additional'),('indicator',0,434,443,'en',0,'Core'),('indicator',0,435,444,'en',0,'Additional'),('indicator',0,436,445,'en',0,'Core'),('indicator',0,437,446,'en',0,'Additional'),('indicator',0,438,447,'en',0,'Additional'),('indicator',0,439,448,'en',0,'Core'),('indicator',0,440,449,'en',0,'Core'),('indicator',0,441,450,'en',0,'Additional'),('indicator',0,442,451,'en',0,'Core'),('indicator',0,443,452,'en',0,'Additional'),('indicator',0,444,453,'en',0,'Additional'),('indicator',0,445,454,'en',0,'Core'),('indicator',0,446,455,'en',0,'Core'),('indicator',0,447,456,'en',0,'Additional'),('indicator',0,448,457,'en',0,'Additional'),('indicator',0,449,458,'en',0,'Core'),('indicator',0,450,459,'en',0,'Additional'),('indicator',0,451,460,'en',0,'Additional'),('indicator',0,452,461,'en',0,'Additional'),('indicator',0,453,462,'en',0,'Additional'),('indicator',0,454,463,'en',0,'Core'),('indicator',0,455,464,'en',0,'Additional'),('indicator',0,456,465,'en',0,'Additional'),('indicator',0,457,466,'en',0,'Core'),('indicator',0,458,467,'en',0,'Additional'),('indicator',0,459,468,'en',0,'Additional'),('indicator',0,460,469,'en',0,'Core'),('indicator',0,461,470,'en',0,'Additional'),('indicator',0,462,471,'en',0,'Additional'),('indicator',0,463,472,'en',0,'Core'),('indicator',0,464,473,'en',0,'Core'),('indicator',0,465,474,'en',0,'Additional'),('indicator',0,466,475,'en',0,'Additional'),('indicator',0,467,476,'en',0,'Core'),('indicator',0,468,477,'en',0,'Additional'),('indicator',0,469,478,'en',0,'Additional'),('indicator',0,470,479,'en',0,'Core'),('indicator',0,471,480,'en',0,'Additional'),('indicator',0,472,481,'en',0,'Additional'),('indicator',0,473,482,'en',0,'Core'),('indicator',0,474,483,'en',0,'Additional'),('indicator',0,475,484,'en',0,'Core'),('indicator',0,476,485,'en',0,'Additional'),('indicator',0,477,486,'en',0,'Additional'),('indicator',0,478,487,'en',0,'Additional'),('indicator',0,479,488,'en',0,'Core'),('indicator',0,480,489,'en',0,'Additional'),('indicator',0,481,490,'en',0,'Additional'),('indicator',0,482,491,'en',0,'Core'),('indicator',0,483,492,'en',0,'Additional'),('indicator',0,484,493,'en',0,'Core'),('indicator',0,485,494,'en',0,'Additional'),('indicator',0,486,495,'en',0,'Additional'),('indicator',0,487,496,'en',0,'Additional'),('indicator',0,488,497,'en',0,'Core'),('indicator',0,489,498,'en',0,'Additional'),('indicator',0,490,499,'en',0,'Additional'),('indicator',0,491,500,'en',0,'Core'),('indicator',0,492,501,'en',0,'Additional'),('indicator',0,493,502,'en',0,'Additional'),('indicator',0,494,503,'en',0,'Core'),('indicator',0,495,504,'en',0,'Additional'),('indicator',0,496,505,'en',0,'Additional'),('indicator',0,497,506,'en',0,'Core'),('indicator',0,498,507,'en',0,'Core'),('indicator',0,499,508,'en',0,'Core'),('indicator',0,500,509,'en',0,'Additional'),('indicator',0,501,510,'en',0,'Additional'),('indicator',0,502,511,'en',0,'Additional'),('indicator',0,503,512,'en',0,'Core'),('indicator',0,504,513,'en',0,'Additional'),('indicator',0,505,514,'en',0,'Additional'),('indicator',0,506,515,'en',0,'Core'),('indicator',0,507,516,'en',0,'Core'),('indicator',0,508,517,'en',0,'Additional'),('indicator',0,509,518,'en',0,'Additional'),('indicator',0,510,519,'en',0,'Core'),('indicator',0,512,521,'en',0,'Core'),('indicator',0,547,557,'en',0,'Additional'),('indicator',0,548,558,'en',0,'Additional'),('indicator',0,549,559,'en',0,'Core'),('indicator',0,550,560,'en',0,'Core'),('indicator',0,551,561,'en',0,'Core'),('indicator',0,552,562,'en',0,'Core'),('indicator',0,553,563,'en',0,'Core'),('indicator',0,554,564,'en',0,'Core'),('indicator',0,585,612,'en',0,'Core');

--
-- Table structure for table `node__field_data_type_representation`
--

CREATE TABLE `node__field_data_type_representation` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_data_type_representation_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_data_type_representation_value` (`field_data_type_representation_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_data_type_representation.';

--
-- Dumping data for table `node__field_data_type_representation`
--

INSERT INTO `node__field_data_type_representation` VALUES ('indicator',0,399,408,'en',0,'Qualitative'),('indicator',0,400,409,'en',0,'Quantitative'),('indicator',0,401,410,'en',0,'Quantitative'),('indicator',0,402,411,'en',0,'Quantitative/Qualitative'),('indicator',0,403,412,'en',0,'Qualitative'),('indicator',0,404,413,'en',0,'Qualitative'),('indicator',0,405,414,'en',0,'Quantitative'),('indicator',0,406,415,'en',0,'Quantitative'),('indicator',0,407,416,'en',0,'Quantitative'),('indicator',0,408,417,'en',0,'Quantitative'),('indicator',0,409,418,'en',0,'Quantitative'),('indicator',0,410,419,'en',0,'Quantitative'),('indicator',0,411,420,'en',0,'Quantitative'),('indicator',0,412,421,'en',0,'Quantitative'),('indicator',0,413,422,'en',0,'Quantitative/Qualitative'),('indicator',0,414,423,'en',0,'Quantitative'),('indicator',0,415,424,'en',0,'Quantitative/Qualitative'),('indicator',0,416,425,'en',0,'Quantitative/Qualitative'),('indicator',0,417,426,'en',0,'Quantitative'),('indicator',0,418,427,'en',0,'Quantitative'),('indicator',0,419,428,'en',0,'Quantitative'),('indicator',0,420,429,'en',0,'Quantitative'),('indicator',0,421,430,'en',0,'Qualitative'),('indicator',0,422,431,'en',0,'Quantitative/Qualitative'),('indicator',0,423,432,'en',0,'Quantitative'),('indicator',0,424,433,'en',0,'Qualitative'),('indicator',0,425,434,'en',0,'Quantitative'),('indicator',0,426,435,'en',0,'Qualitative'),('indicator',0,427,436,'en',0,'Quantitative'),('indicator',0,428,437,'en',0,'Quantitative'),('indicator',0,429,438,'en',0,'Quantitative'),('indicator',0,430,439,'en',0,'Quantitative'),('indicator',0,431,440,'en',0,'Qualitative'),('indicator',0,432,441,'en',0,'Quantitative'),('indicator',0,433,442,'en',0,'Quantitative'),('indicator',0,434,443,'en',0,'Qualitative'),('indicator',0,435,444,'en',0,'Quantitative'),('indicator',0,436,445,'en',0,'Quantitative'),('indicator',0,437,446,'en',0,'Quantitative/Qualitative'),('indicator',0,438,447,'en',0,'Qualitative'),('indicator',0,439,448,'en',0,'Quantitative'),('indicator',0,440,449,'en',0,'Qualitative'),('indicator',0,441,450,'en',0,'Qualitative'),('indicator',0,442,451,'en',0,'Quantitative/Qualitative'),('indicator',0,443,452,'en',0,'Quantitative'),('indicator',0,444,453,'en',0,'Quantitative'),('indicator',0,445,454,'en',0,'Qualitative'),('indicator',0,446,455,'en',0,'Quantitative'),('indicator',0,447,456,'en',0,'Quantitative'),('indicator',0,448,457,'en',0,'Quantitative'),('indicator',0,449,458,'en',0,'Quantitative'),('indicator',0,450,459,'en',0,'Quantitative'),('indicator',0,451,460,'en',0,'Quantitative'),('indicator',0,452,461,'en',0,'Qualitative'),('indicator',0,453,462,'en',0,'Qualitative'),('indicator',0,454,463,'en',0,'Qualitative'),('indicator',0,455,464,'en',0,'Qualitative'),('indicator',0,456,465,'en',0,'Qualitative'),('indicator',0,457,466,'en',0,'Quantitative'),('indicator',0,458,467,'en',0,'Quantitative'),('indicator',0,459,468,'en',0,'Qualitative'),('indicator',0,460,469,'en',0,'Quantitative'),('indicator',0,461,470,'en',0,'Qualitative'),('indicator',0,462,471,'en',0,'Qualitative'),('indicator',0,463,472,'en',0,'Qualitative'),('indicator',0,464,473,'en',0,'Qualitative'),('indicator',0,465,474,'en',0,'Qualitative'),('indicator',0,466,475,'en',0,'Qualitative'),('indicator',0,467,476,'en',0,'Quantitative/Qualitative'),('indicator',0,468,477,'en',0,'Qualitative'),('indicator',0,469,478,'en',0,'Qualitative'),('indicator',0,470,479,'en',0,'Quantitative'),('indicator',0,471,480,'en',0,'Quantitative'),('indicator',0,472,481,'en',0,'Quantitative'),('indicator',0,473,482,'en',0,'Quantitative'),('indicator',0,474,483,'en',0,'Qualitative'),('indicator',0,475,484,'en',0,'Quantitative/Qualitative'),('indicator',0,476,485,'en',0,'Quantitative'),('indicator',0,477,486,'en',0,'Quantitative/Qualitative'),('indicator',0,478,487,'en',0,'Qualitative'),('indicator',0,479,488,'en',0,'Quantitative/Qualitative'),('indicator',0,480,489,'en',0,'Quantitative'),('indicator',0,481,490,'en',0,'Quantitative'),('indicator',0,482,491,'en',0,'Quantitative'),('indicator',0,483,492,'en',0,'Quantitative'),('indicator',0,484,493,'en',0,'Quantitative'),('indicator',0,485,494,'en',0,'Qualitative'),('indicator',0,486,495,'en',0,'Quantitative'),('indicator',0,487,496,'en',0,'Quantitative'),('indicator',0,488,497,'en',0,'Quantitative'),('indicator',0,489,498,'en',0,'Qualitative'),('indicator',0,490,499,'en',0,'Quantitative'),('indicator',0,491,500,'en',0,'Qualitative'),('indicator',0,492,501,'en',0,'Quantitative'),('indicator',0,493,502,'en',0,'Quantitative/Qualitative'),('indicator',0,494,503,'en',0,'Quantitative'),('indicator',0,495,504,'en',0,'Quantitative/Qualitative'),('indicator',0,496,505,'en',0,'Quantitative'),('indicator',0,497,506,'en',0,'Qualitative'),('indicator',0,498,507,'en',0,'Qualitative'),('indicator',0,499,508,'en',0,'Quantitative'),('indicator',0,500,509,'en',0,'Qualitative'),('indicator',0,501,510,'en',0,'Quantitative'),('indicator',0,502,511,'en',0,'Quantitative'),('indicator',0,503,512,'en',0,'Quantitative/Qualitative'),('indicator',0,504,513,'en',0,'Qualitative'),('indicator',0,505,514,'en',0,'Qualitative'),('indicator',0,506,515,'en',0,'Quantitative'),('indicator',0,507,516,'en',0,'Quantitative'),('indicator',0,508,517,'en',0,'Quantitative'),('indicator',0,509,518,'en',0,'Quantitative'),('indicator',0,510,519,'en',0,'Qualitative'),('indicator',0,512,521,'en',0,'Qualitative'),('indicator',0,547,557,'en',0,'Qualitative'),('indicator',0,548,558,'en',0,'Qualitative'),('indicator',0,549,559,'en',0,'Quantitative'),('indicator',0,550,560,'en',0,'Quantitative'),('indicator',0,551,561,'en',0,'Quantitative'),('indicator',0,552,562,'en',0,'Quantitative'),('indicator',0,553,563,'en',0,'Quantitative'),('indicator',0,554,564,'en',0,'Quantitative'),('indicator',0,585,612,'en',0,'Quantitative');

--
-- Table structure for table `node__field_description`
--

CREATE TABLE `node__field_description` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_description_value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_description.';

--
-- Dumping data for table `node__field_description`
--

INSERT INTO `node__field_description` VALUES ('indicator',0,399,408,'en',0,'The initiative/project applies an intellectual property strategy that is conducive to facilitating access to medicine, operating in accordance with the international consensus on intellectual property standards as it pertains to public health, confirmed by the Doha Declaration.'),('indicator',0,400,409,'en',0,'Deviations related to the schedule or costs of health research processes.'),('indicator',0,401,410,'en',0,'Number of observations/audits carried out during a specific period of time to monitor the results expected of health research processes.'),('indicator',0,402,411,'en',0,'Description and measurement of the impacts of commercializing the outputs of research (e.g. drugs, treatments) on the economy.'),('indicator',0,403,412,'en',0,'Description of the economic impact on workforce related to the improvement of employees\' health and wellbeing as a consequence of the initiative/project\'s research findings.'),('indicator',0,404,413,'en',0,'Description of the economic effects of the initiative/project\'s research findings on  communities.'),('indicator',0,405,414,'en',0,'Direct economic value generated by the initiative/project, i.e. revenues as well as economic value distributed (operating costs, employee wages and benefits, payments to providers of capital, payments to government by country, and community investments).'),('indicator',0,406,415,'en',0,'Return on investment (ROI) for the research initiative/project. Comparison between the net income obtained or expected to be obtained relative to the cost of investments (value of the assets devoted to their obtention).'),('indicator',0,407,416,'en',0,'Percentage of the level of debt incurred by an initiative/project compared to the income generated by its research activity.'),('indicator',0,408,417,'en',0,'Percentage that the revenues obtained from research patents and other intellectual property rights represent with respect to their book value.'),('indicator',0,409,418,'en',0,'Cost-benefit ratio of healthcare practice'),('indicator',0,410,419,'en',0,'Value of the revenues obtained from the exploitation of patents and other intellectual property rights.'),('indicator',0,411,420,'en',0,'Number and percentage of achieved health research initiative/project\'s milestones.'),('indicator',0,412,421,'en',0,'Number of past/potential products and treatments resulting from the outcomes of the research initiative/project.'),('indicator',0,413,422,'en',0,'Describe the perception of and relationships to the different stakeholders related to the research initiative/project.'),('indicator',0,414,423,'en',0,'Cost per unit produced (product/service/contracted process)'),('indicator',0,415,424,'en',0,'Analysis of the influence of the research carried out by the initiative/project on the cost-containment and cost-effectiveness of health services.'),('indicator',0,416,425,'en',0,'Number and description of drug recalls of products produced by the initiative/project.'),('indicator',0,417,426,'en',0,'Number of jobs created/expected.'),('indicator',0,418,427,'en',0,'Total number and percentage of employees of the initiative/project by age group, gender and region.'),('indicator',0,419,428,'en',0,'Average and increase/decrease of the number of medications used to treat a certain disease.'),('indicator',0,420,429,'en',0,'Patients treated without drugs for the disease on which the research of the initiative/project focuses over the target screened population. The indicator measures the degree to which primary care prescribers treat patients seeking curative care with non-pharmaceutical therapies.'),('indicator',0,421,430,'en',0,'Description of the governance structures to manage and monitor HSO that result from the implementation of research results.'),('indicator',0,422,431,'en',0,'Description of the degree of the initiative/project\'s impact on health benefits as direct/considerable/moderate/identifiable.'),('indicator',0,423,432,'en',0,'Percentage of the population screened for the disease on which the initiative/project focuses per year over the target screened population. When possible, provide the percentage of population screened disaggregated by gender.'),('indicator',0,424,433,'en',0,'Description of the digital eHealth/eServices technologies available and used by the initiative/project, such as Unique patient ID, linked records, or scale teleservices.'),('indicator',0,425,434,'en',0,'Coverage of essential services related to reproductive, maternal, newborn and child health, infectious diseases, non-communicable diseases and service capacity and access, among the whole population of PwMS.'),('indicator',0,426,435,'en',0,'The initiative/project, particularly those developed by pharma companies, publicly reports information on access to medicine.'),('indicator',0,427,436,'en',0,'Equity of access to healthcare on a gender or ethnic basis (or other marginalized groups).'),('indicator',0,428,437,'en',0,'Health interventions undertaken by using a multidisciplinary team over the whole interventions of the population of PwMS.'),('indicator',0,429,438,'en',0,'Number of training courses available for health professionals, both of the initiative/project or of other organizations.'),('indicator',0,430,439,'en',0,'Number of university-employed clinical academics, disagreggated by gender, that participate in the initiative/project.'),('indicator',0,431,440,'en',0,'Description of the qualitative improvements produced by health research in the health care service delivery process applied to the whole population of PwMS.'),('indicator',0,432,441,'en',0,'Risk stratification index (RSI) helps to assess risks and to make comparisons of the outcomes, for instance, in terms of duration of stay and mortality.'),('indicator',0,433,442,'en',0,'Number of hospital admissions that could be prevented by means of preventative health interventions and/or early detecion and disease management prior to hospital admission.'),('indicator',0,434,443,'en',0,'A safety plan documents the process for identifying and managing the possible physical and health hazards as well as the specific safety goals related to the work environment.'),('indicator',0,435,444,'en',0,'Number and type of guidelines/tools developed for patients.'),('indicator',0,436,445,'en',0,'Quality Adjusted Life Year is a method to evaluate the health outcomes of interventions (combined with the costs) including both the quality and the quantity of life.'),('indicator',0,437,446,'en',0,'Mortality rate of patients in which the initiative/project\'s research focuses on and description of the contribution to reduce that rate.'),('indicator',0,438,447,'en',0,'Description of the expected contributions of the initiative/project to increase overall life expectancy.'),('indicator',0,439,448,'en',0,'Percentage change in how patients are satisfied with the care received.'),('indicator',0,440,449,'en',0,'Description of the collaboration with other societal stakeholders in health promotion.'),('indicator',0,441,450,'en',0,'Description of the engagement activities with relevant patient groups.'),('indicator',0,442,451,'en',0,'Number of publications produced by the initiative/project, differentiating the key subject under study and whether or not they are peer-reviewed, and percentage of those articles published in high-impact journals.'),('indicator',0,443,452,'en',0,'Number of publications with co-authors affiliated to organizations in different countries and sectors.'),('indicator',0,444,453,'en',0,'Number and percentage of open access publications (differentiating between green and gold open access when possible).'),('indicator',0,445,454,'en',0,'Degree of anticipatory design in health research processes.'),('indicator',0,446,455,'en',0,'Number of citations in academic publications.'),('indicator',0,447,456,'en',0,'Diffusion score of the applicability of new knowledge: balance and distribution of citations from various fields.'),('indicator',0,448,457,'en',0,'Number of studies produced by the initiative/project that have been cited in guidelines issued by a government agency, an organization related to the field of study, or a non-governmental organization.'),('indicator',0,449,458,'en',0,'Number of dissemination/outreach activities other than peer-reviewed publications (e.g. conferences, workshops, press releases, media/social media campaigns).'),('indicator',0,450,459,'en',0,'Number of media hits and press articles raising awareness on the initiative/project research activities.'),('indicator',0,451,460,'en',0,'Assessment of the reach and accessibility of the webpage of the initiative/project.'),('indicator',0,452,461,'en',0,'Description of the extent to the initiative/project complies with clinical guidelines.'),('indicator',0,453,462,'en',0,'Description of the processes that the initiative/project follows to identify potential risks related to the research process and how these risks are managed.'),('indicator',0,454,463,'en',0,'Indication of the existence of an ethical committee to manage research, and description of its structure (indicating its composition and gender distribution) and functions.'),('indicator',0,455,464,'en',0,'Overview of the initiative/project’s values, principles and standards, specifying how they have been approved, developed, and implemented in the health research process.'),('indicator',0,456,465,'en',0,'Describe whether and how the health research initiative/project integrated any type of ethical assessment/review in its funding decisions.'),('indicator',0,457,466,'en',0,'Number of grants and their monetary amount.'),('indicator',0,458,467,'en',0,'Collaborative research projects funded through joint calls that address the scientific priorities identified by the initiative.'),('indicator',0,459,468,'en',0,'Indication of whether and how the initiative/project takes public engagement elements into account for the development or evaluation of R&I projects.'),('indicator',0,460,469,'en',0,'Number of the new taxonomies of diseases and new stratifications developed, published or implemented.'),('indicator',0,461,470,'en',0,'Description of the overall impacts for patients generated by the initiative/project.'),('indicator',0,462,471,'en',0,'Description of the overall impacts for society generated by the initiative/project.'),('indicator',0,463,472,'en',0,'Description of the expected or targeted changes in knowledge, attitudes and behavior as a result of research dissemination and implementation strategies.'),('indicator',0,464,473,'en',0,'Level of contributions to follow-on research (e.g. pilot studies, implementation projects, methodological frameworks).'),('indicator',0,465,474,'en',0,'Description of the influence of the initiative/project on shaping the R&D agenda.'),('indicator',0,466,475,'en',0,'Description of the changes in national research priorities (new or updated) so that the initiative/project can align their own to these changes.'),('indicator',0,467,476,'en',0,'Number and type of applicable project outputs (e.g. clinical guidelines, protocol standards, care practices or healthcare training) in policy development or in practice settings.'),('indicator',0,468,477,'en',0,'Description of the utilization of evidence-based knowledge/advice developed by the initiative/project in policy-making processes.'),('indicator',0,469,478,'en',0,'Description of the use of research outcomes of the initiative/project by clinical decision-makers.'),('indicator',0,470,479,'en',0,'Percentage of patents and other intellectual property rights owned by the research initiative that are being or have been exploited by the pharma industry.'),('indicator',0,471,480,'en',0,'Number of research institutions with which the initiative/project shares their intellectual property rights and research findings to develop new drugs or treatments.'),('indicator',0,472,481,'en',0,'Number of patents and other property rights owned by the initiative and awarded during the reporting period. When possible, the initiative should break down the patents and other intellectual property rights considering the time horizon for its exploitation, the country where it was awarded, and whether they are produced, commercialized or provisional.'),('indicator',0,473,482,'en',0,'Number of advanced phase clinical/pragmatic trials and/or Public Health research project where patient have been engaged.'),('indicator',0,474,483,'en',0,'Description of how the initiative/project involves potential users in the research process.'),('indicator',0,475,484,'en',0,'Number of new drugs and products developed by the initiative. Indicate the products and drugs in the pipeline, indicating their stage.'),('indicator',0,476,485,'en',0,'Number of novel therapeutic advances developed by the initiative/project during the reporting period, such as biomarkers, medical treatments, devices etc.'),('indicator',0,477,486,'en',0,'Spin-offs resulting from the development of research results.'),('indicator',0,478,487,'en',0,'Description of the potential effects of new products and developments of the initiative/project (e.g. novel or improved drugs, therapeutic advances or other medical interventions) on patients\' wellbeing.'),('indicator',0,479,488,'en',0,'Number and description of the collaboration types in research activities (purpose, activities, target audiences).'),('indicator',0,480,489,'en',0,'Share of projects involving patient organizations and healthcare professionals\' associations as partners/members of advisory boards.'),('indicator',0,481,490,'en',0,'Number of consortia that applied for translational funding with the initiative/project.'),('indicator',0,482,491,'en',0,'Research leadership in terms of impact of the research awareness considering: (i) number and type of public recognitions, (ii) number of editorial board served, (iii) number of research bodies.'),('indicator',0,483,492,'en',0,'Number and type of research awards given to initiative/project\'s researchers and/or programmes.'),('indicator',0,484,493,'en',0,'Number and type of highly skilled people supported, disaggregated by gender.'),('indicator',0,485,494,'en',0,'Description of the technical and scientific competency of staff.'),('indicator',0,486,495,'en',0,'Number of women on the committees of the initiative/project and share of females over the total number of committee members.'),('indicator',0,487,496,'en',0,'Share of female researchers over the total number of researchers.'),('indicator',0,488,497,'en',0,'Total amount of financial R&D investments.'),('indicator',0,489,498,'en',0,'Description of the overall organizational structure specific to conduct research of the initiative/project.'),('indicator',0,490,499,'en',0,'Percentage of projects with a significant impact of \"knowledge work\".'),('indicator',0,491,500,'en',0,'Description of the governance structures of the initiative/project (specifying their composition and gender distribution) and procedures that have been established to manage and monitor the research process.'),('indicator',0,492,501,'en',0,'Number of outreach visits by researchers and number of attendees at outreach visits.'),('indicator',0,493,502,'en',0,'Number of and description of research methodologies that have been developed or improved.'),('indicator',0,494,503,'en',0,'Number and type of target groups attending organized events.'),('indicator',0,495,504,'en',0,'Number and description of mechanisms applied to interact with citizens and societal stakeholders.'),('indicator',0,496,505,'en',0,'Number of stakeholders consulted by the research initiative/project.'),('indicator',0,497,506,'en',0,'Description of the social reputation of the research project/initiative.'),('indicator',0,498,507,'en',0,'Indication of whether the initiative/project has clearly defined enforcement procedures and, if there have been  misconducts, evidence of taking disciplinary action against employees or third parties who have violated its code of conduct for ethical marketing or anti-corruption. The initiative/project provides evidence of follow-up actions taken to mitigate the risk of future breaches.'),('indicator',0,499,508,'en',0,'Number of employee accidents and infections in laboratory facilities,'),('indicator',0,500,509,'en',0,'Significant actual and potential impact on labour practices driven by the research initiative/project.'),('indicator',0,501,510,'en',0,'Employee turnover during the reporting period by age group and gender at the local/regional/national levels.'),('indicator',0,502,511,'en',0,'Average hours of training programs for research employees, disaggregated by gender group, in the reporting period relative to the average number of research employees.'),('indicator',0,503,512,'en',0,'Description and number of policies and guidelines informed by the research initiative/project.'),('indicator',0,504,513,'en',0,'Description and number of adopted measures to improve the governance and organization of the project/initiative\'s research activities.'),('indicator',0,505,514,'en',0,'Description of the interaction between the research initiative/project and external relevant actors (e.g. government agencies).'),('indicator',0,506,515,'en',0,'Number of environmental audits conducted within the initiative/project.'),('indicator',0,507,516,'en',0,'Quantity of raw materials needed for manufacturing purposes (during the research and production processes).'),('indicator',0,508,517,'en',0,'Amount of greenhouse gas (GHG) emissions from activities carried out by the initiative/project. The main gases to be considered are carbon dioxide (CO2), methane (CH4), nitrous oxide (N2O) and hydrofluorocarbons (HFCs), among others.'),('indicator',0,509,518,'en',0,'Implemented actions for enhancing local community engagement, impact assessments, and development programs based on local needs.'),('indicator',0,510,519,'en',0,'Description of the activities organized by the initiative/project to promote the engagement with community members.'),('indicator',0,512,521,'en',0,'Description of the extent to which standards and regulations regarding RRI are acknowledged, complied with and embedded in the research process of the initiative/project.'),('indicator',0,547,557,'en',0,'Description of the engagement with clinicians and patients for the implementation of research strategies and research outcomes in health care practice.'),('indicator',0,548,558,'en',0,'Disclosure of public reports about the economic, social and environmental impacts resulting from the initiative/project\'s research and how these impact are being managed.'),('indicator',0,549,559,'en',0,'Percentage change in how patients are satisfied with their level of Anxiety and Depression after the care received (self reported) '),('indicator',0,550,560,'en',0,'Percentage change in how patients are satisfied with their level of functional domains evaluated by the scale after the care received (self reported) '),('indicator',0,551,561,'en',0,'Percentage change in how patients are satisfied with their level of bladder functions after the care received (self reported) '),('indicator',0,552,562,'en',0,'Percentage change in how patients are satisfied with their level of motor, cognitive, psyco-social fatigue after the care received (self reported) '),('indicator',0,553,563,'en',0,'Percentage change in how patients are satisfied after the care received (self reported) '),('indicator',0,554,564,'en',0,'Percentage change in how patients are satisfied with their level of upper-limb dexterity after the care received (self reported) \r\n'),('indicator',0,585,612,'en',0,'Percentage change in how patients are satisfied with their level of locomotion after the care received (self reported) ');

--
-- Table structure for table `node__field_dimension`
--

CREATE TABLE `node__field_dimension` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_dimension_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the target entity.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_dimension_target_id` (`field_dimension_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_dimension.';

--
-- Dumping data for table `node__field_dimension`
--

INSERT INTO `node__field_dimension` VALUES ('impact_analysis',0,532,542,'en',0,10),('impact_analysis',0,533,543,'en',0,10),('impact_analysis',0,559,577,'en',0,10),('impact_analysis',0,560,578,'en',0,11),('impact_analysis',0,561,579,'en',0,13),('impact_analysis',0,562,580,'en',0,11),('impact_analysis',0,563,581,'en',0,14),('impact_analysis',0,565,583,'en',0,10),('impact_analysis',0,566,584,'en',0,13),('impact_analysis',0,567,585,'en',0,48),('impact_analysis',0,568,586,'en',0,11),('impact_analysis',0,569,587,'en',0,14),('impact_analysis',0,574,601,'en',0,13),('impact_analysis',0,575,602,'en',0,11),('impact_analysis',0,576,603,'en',0,10),('impact_analysis',0,577,604,'en',0,14),('impact_analysis',0,578,605,'en',0,11),('impact_analysis',0,579,606,'en',0,48),('impact_analysis',0,580,607,'en',0,11),('impact_analysis',0,581,608,'en',0,11),('impact_analysis',0,582,609,'en',0,14),('impact_analysis',0,583,610,'en',0,11),('impact_analysis',0,584,611,'en',0,11),('impact_analysis',0,586,613,'en',0,14),('impact_analysis',0,587,614,'en',0,14),('impact_analysis',0,588,615,'en',0,14),('impact_analysis',0,591,620,'en',0,14);

--
-- Table structure for table `node__field_example`
--

CREATE TABLE `node__field_example` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_example_value` longtext NOT NULL,
  `field_example_format` varchar(255) CHARACTER SET ascii DEFAULT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_example_format` (`field_example_format`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_example.';

--
-- Dumping data for table `node__field_example`
--

INSERT INTO `node__field_example` VALUES ('indicator',0,399,408,'en',0,'<img alt=\"Extract from Sanofi CSR report 2011 (p. 463).\" data-align=\"center\" data-caption=\"Extract from Sanofi CSR report 2011 (p. 463).\" data-entity-type=\"file\" data-entity-uuid=\"39d57e0c-e30a-4e96-857f-fab6ea779bce\" src=\"/sites/default/files/inline-images/1.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/publications/33109_CSR_reporting_2011.pdf\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/publications/33109_CSR_reporting_2011.pdf</a></p>\r\n','basic_html'),('indicator',0,400,409,'en',0,'<img alt=\"Extract from McKinsey &amp; Company 2012 (p. 4).\" data-align=\"center\" data-caption=\"Extract from McKinsey &amp;amp; Company 2012 (p. 4).\" data-entity-type=\"file\" data-entity-uuid=\"4ec10ea9-ad28-4540-8bf5-514ea6c16a7b\" src=\"/sites/default/files/inline-images/2_0.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.mckinsey.com/~/media/McKinsey/dotcom/client_service/BTO/PDF/MOBT_27_Delivering_large-scale_IT_projects_on_time_budget_and_value.ashx\">https://www.mckinsey.com/~/media/McKinsey/dotcom/client_service/BTO/PDF/MOBT_27_Delivering_large-scale_IT_projects_on_time_budget_and_value.ashx</a></p>\r\n','basic_html'),('indicator',0,401,410,'en',0,'<img alt=\"Extract from Bayer Annual Report 2017 (p. 105).\" data-align=\"center\" data-caption=\"Extract from Bayer Annual Report 2017 (p. 105).\" data-entity-type=\"file\" data-entity-uuid=\"98907d9d-0d17-4608-b565-edb3d0259b0b\" src=\"/sites/default/files/inline-images/3.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.annualreport2017.bayer.com/downloads.html\">https://www.annualreport2017.bayer.com/downloads.html</a></p>\r\n','basic_html'),('indicator',0,402,411,'en',0,'<img alt=\"Extract from Novartis Corporate Responsibility Report 2017 (p. 15).\" data-align=\"center\" data-caption=\"Extract from Novartis Corporate Responsibility Report 2017 (p. 15).\" data-entity-type=\"file\" data-entity-uuid=\"5728fde1-2cbc-4a83-bb07-23adb83b4596\" src=\"/sites/default/files/inline-images/15_0.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.novartis.com/sites/www.novartis.com/files/novartis-cr-performance-report-2017.pdf\">https://www.novartis.com/sites/www.novartis.com/files/novartis-cr-performance-report-2017.pdf</a></p>\r\n','basic_html'),('indicator',0,405,414,'en',0,'<img alt=\"Extract from Rovi Annual Report 2017 (p .9)\" data-align=\"center\" data-caption=\"Rovi Annual Report 2017 (p .9)\" data-entity-type=\"file\" data-entity-uuid=\"1ae2cb12-cba8-4fa2-89b9-891ce9ffc127\" src=\"/sites/default/files/inline-images/7.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.rovi.es/sites/default/files/MEMORIA_ROVI_2017_EN_%2814-05-2018%29-INTERACTIVE_0.pdf\">https://www.rovi.es/sites/default/files/MEMORIA_ROVI_2017_EN_%2814-05-2018%29-INTERACTIVE_0.pdf</a></p>\r\n','basic_html'),('indicator',0,406,415,'en',0,'<p>For the ROI specific for health research:</p>\r\n<img alt=\"Extract from KPMG, Economic Impact of Medical Research in Australia (2018) (p. 42).\" data-align=\"center\" data-caption=\"Extract from KPMG, Economic Impact of Medical Research in Australia (2018) (p. 42).\" data-entity-type=\"file\" data-entity-uuid=\"f03d1ecc-b135-4533-85d5-7b2a08e8048e\" src=\"/sites/default/files/inline-images/8.1.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://aamri.org.au/wp-content/uploads/2018/10/Economic-Impact-of-Medical-Research-exec-summary.pdf\">https://aamri.org.au/wp-content/uploads/2018/10/Economic-Impact-of-Medical-Research-exec-summary.pdf</a></p>\r\n\r\n<p>For the general ROI (also named as ROCE):</p>\r\n<img alt=\"Extract from Bayer Annual report 2018 (p. 103).\" data-align=\"center\" data-caption=\"Extract from Bayer Annual Report 2018 (p. 103).\" data-entity-type=\"file\" data-entity-uuid=\"554d37be-7b83-4c53-a71f-1a7db6ef04a3\" src=\"/sites/default/files/inline-images/8.2.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.bayer.com/en/bayer-annual-report-2018.pdfx\">https://www.bayer.com/en/bayer-annual-report-2018.pdfx</a></p>\r\n','basic_html'),('indicator',0,409,418,'en',0,'<img alt=\"Extract from &quot;Exceptional returns: the value of investing in health R&amp;D in Australia II&quot; (pp. 34).\" data-align=\"center\" data-caption=\"Extract from &quot;Exceptional returns: the value of investing in health R&amp;amp;D in Australia II&quot; (pp. 34).\" data-entity-type=\"file\" data-entity-uuid=\"3f76c2ea-55f1-4ff8-9048-3204b8445794\" src=\"/sites/default/files/inline-images/11.1_0.png\" /><img alt=\"Extract from &quot;Exceptional returns: the value of investing in health R&amp;D in Australia II&quot; (pp. 35).\" data-align=\"center\" data-caption=\"Extract from &quot;Exceptional returns: the value of investing in health R&amp;amp;D in Australia II&quot; (pp. 35).\" data-entity-type=\"file\" data-entity-uuid=\"0e94fb97-2d93-4d42-a1ba-7cbcad37af8c\" src=\"/sites/default/files/inline-images/11.2.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://asmr.org.au/wp-content/uploads/library/ExceptII08.pdf\">https://asmr.org.au/wp-content/uploads/library/ExceptII08.pdf</a></p>\r\n','basic_html'),('indicator',0,410,419,'en',0,'<img alt=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 33).\" data-align=\"center\" data-caption=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 33).\" data-entity-type=\"file\" data-entity-uuid=\"629742d5-99a9-4967-9c49-e7e2846ff73f\" src=\"/sites/default/files/inline-images/12.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf\">https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf</a></p>\r\n','basic_html'),('indicator',0,411,420,'en',0,'<img alt=\"Extract from Australia and New Zealand CRC for Spatial Information Annual Report 2016-17 (p. 9).\" data-align=\"center\" data-caption=\"Extract from Australia and New Zealand CRC for Spatial Information Annual Report 2016-17 (p. 9).\" data-entity-type=\"file\" data-entity-uuid=\"50803b34-38ac-4718-b03e-a94cfe778b8b\" src=\"/sites/default/files/inline-images/13.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.crcsi.com.au/assets/Resources/CRCSI-AnnualReport2017-web.pdf\">https://www.crcsi.com.au/assets/Resources/CRCSI-AnnualReport2017-web.pdf</a></p>\r\n','basic_html'),('indicator',0,412,421,'en',0,'<img alt=\"Extract from Sanofi Integrated Report 2018 (p. 6).\" data-align=\"center\" data-caption=\"Extract from Sanofi Integrated Report 2018 (p. 6).\" data-entity-type=\"file\" data-entity-uuid=\"ae6e372a-55ec-459f-807c-73184d48b56c\" src=\"/sites/default/files/inline-images/14_0.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/about-us/Sanofi-RI2018-EN-PDF-e-accessible_02.pdf?la=en\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/about-us/Sanofi-RI2018-EN-PDF-e-accessible_02.pdf?la=en</a></p>\r\n','basic_html'),('indicator',0,417,426,'en',0,'<img alt=\"Extract from PhRMA web page.\" data-align=\"center\" data-caption=\"Extract from PhRMA web page.\" data-entity-type=\"file\" data-entity-uuid=\"e4ea07e1-1de1-4fa6-9760-884153944c35\" src=\"/sites/default/files/inline-images/19.png\" />\r\n<p>Available at:<a href=\"https://www.phrma.org/media/industry-economic-impact\">https://www.phrma.org/media/industry-economic-impact</a></p>\r\n','basic_html'),('indicator',0,418,427,'en',0,'<img alt=\"Extract from Bayer Annual Report 2018 (p. 53).\" data-align=\"center\" data-caption=\"Extract from Bayer Annual Report 2018 (p. 53).\" data-entity-type=\"file\" data-entity-uuid=\"34dad937-fd41-42d7-822c-5778b845bd30\" src=\"/sites/default/files/inline-images/20.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.bayer.com/en/bayer-annual-report-2018.pdfx\">https://www.bayer.com/en/bayer-annual-report-2018.pdfx</a></p>\r\n','basic_html'),('indicator',0,419,428,'en',0,'<img alt=\"Extract from Frahm et al. (2018) (p. 5).\" data-align=\"center\" data-caption=\"Extract from Frahm et al. (2018) (p. 5).\" data-entity-type=\"file\" data-entity-uuid=\"1f5f82e9-9894-4d9d-ab54-c25c9fb564a0\" src=\"/sites/default/files/inline-images/21.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.nature.com/articles/s41598-019-40283-5\">https://www.nature.com/articles/s41598-019-40283-5</a></p>\r\n','basic_html'),('indicator',0,420,429,'en',0,'<img alt=\"Table 3 in Thiruthopu et al. (2014). Drug utilization pattern in South Indian pediatric population: A prospective study. Perspectives in clinical research, 5(4).\" data-align=\"center\" data-caption=\"Table 3 in Thiruthopu et al. (2014). Drug utilization pattern in South Indian pediatric population: A prospective study. Perspectives in clinical research, 5(4).\" data-entity-type=\"file\" data-entity-uuid=\"95d6565f-3bcf-4ef1-a494-c92c8fe33ff0\" src=\"/sites/default/files/inline-images/22.png\" />\r\n<p>&nbsp;</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170536/\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170536/</a></p>\r\n','basic_html'),('indicator',0,423,432,'en',0,'<p>See the National Comprehensive Cancer Control Program (NCCCP), Colorectal Cancer Screening Rates.&nbsp;For instance:</p>\r\n<img alt=\"Extract from Comprehensive Cancer Control Program (NCCCP).\" data-align=\"center\" data-caption=\"Extract from Comprehensive Cancer Control Program (NCCCP)\" data-entity-type=\"file\" data-entity-uuid=\"34e7bd97-3965-42f1-8d14-f24f7e1d83ef\" src=\"/sites/default/files/inline-images/25.png\" />\r\n<p>Available at&nbsp;<a href=\"https://www.cdc.gov/cancer/ncccp/screening-rates/ \">https://www.cdc.gov/cancer/ncccp/screening-rates/ </a></p>\r\n','basic_html'),('indicator',0,424,433,'en',0,'<img alt=\"Extract from Finland: Healthcare system and eHealth strategy (p. 11)\" data-align=\"center\" data-caption=\"Extract from Finland: Healthcare system and eHealth strategy (p. 11)\" data-entity-type=\"file\" data-entity-uuid=\"f03bc1a7-97c3-447e-a884-511f3cc1b098\" src=\"/sites/default/files/inline-images/26.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://ec.europa.eu/health/sites/health/files/ehealth/docs/ev_20150512_co53_en.pdf\">https://ec.europa.eu/health/sites/health/files/ehealth/docs/ev_20150512_co53_en.pdf</a></p>\r\n','basic_html'),('indicator',0,425,434,'en',0,'<img alt=\"Extract from Tracking Universal Health Coverage - WHO (p. 21).\" data-align=\"center\" data-caption=\"Extract from Tracking Universal Health Coverage - WHO (p. 21).\" data-entity-type=\"file\" data-entity-uuid=\"f9c274f5-a6ec-494e-afab-3ea6ce26b4ca\" src=\"/sites/default/files/inline-images/27.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://apps.who.int/iris/bitstream/handle/10665/174536/9789241564977_eng.pdf;jsessionid=FB2C13C6BAE47431FF604534502C84C0?sequence=1\">https://apps.who.int/iris/bitstream/handle/10665/174536/9789241564977_eng.pdf;jsessionid=FB2C13C6BAE47431FF604534502C84C0?sequence=1</a></p>\r\n','basic_html'),('indicator',0,426,435,'en',0,'<p>Example on how GSK offers information on access to medicine:</p>\r\n<img alt=\"​​Extract from GSK ESG Summary 2018 (pp. 2-3).\" data-align=\"center\" data-caption=\"​​Extract from GSK ESG Performance Summary 2018 (p. 2).\" data-entity-type=\"file\" data-entity-uuid=\"d5ee8902-7547-4366-8676-8101d168bc0b\" src=\"/sites/default/files/inline-images/28.1_0.png\" /><img alt=\"​​Extract from GSK ESG Summary 2018 (pp. 2-3).\" data-align=\"center\" data-caption=\"​​Extract from GSK ESG Performance Summary 2018 (p. 3).\" data-entity-type=\"file\" data-entity-uuid=\"99199ed9-09e8-4142-9472-c0536e92947f\" src=\"/sites/default/files/inline-images/28.2.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.gsk.com/media/5308/esg-performance-summary-2018.pdf\">https://www.gsk.com/media/5308/esg-performance-summary-2018.pdf</a></p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,427,436,'en',0,'<img alt=\"Extract from Inequalities in access to healthcare - A study of national policies (p. 37).\" data-align=\"center\" data-caption=\"Extract from &quot;Inequalities in access to healthcare - A study of national policies&quot; (p. 37).\" data-entity-type=\"file\" data-entity-uuid=\"ebdab83f-7380-4dab-b24d-7df48e8cca5f\" src=\"/sites/default/files/inline-images/29.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://ec.europa.eu/social/main.jsp?catId=738&amp;langId=en&amp;pubId=8152&amp;furtherPubs=yes\">https://ec.europa.eu/social/main.jsp?catId=738&amp;langId=en&amp;pubId=8152&amp;furtherPubs=yes</a></p>\r\n','basic_html'),('indicator',0,429,438,'en',0,'<p>The report \"Understanding the development needs of the primary care and community health workforces with regard to sexual health in NHSScotland to enable the successful implementation of ‘The Sexual Health and Blood Borne Virus&nbsp;Framework 2011-2015’: a scoping study\". Report for NHS Scotland&nbsp;(pp. 19-29 show examples of existing training).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://pdfs.semanticscholar.org/f2c1/8ab9a6d6b7a3c49d92bffa39c192ca36cd5e.pdf\">https://pdfs.semanticscholar.org/f2c1/8ab9a6d6b7a3c49d92bffa39c192ca36cd5e.pdf</a></p>\r\n','basic_html'),('indicator',0,430,439,'en',0,'<img alt=\"Extract from Vall D\'Hebron Strategic Plan 2011-15 (p. 34)\" data-align=\"center\" data-caption=\"Extract from Vall D\'Hebron Strategic Plan 2011-15 (p. 34)\" data-entity-type=\"file\" data-entity-uuid=\"406670e0-0440-4d47-bdf3-f65053fcd325\" src=\"/sites/default/files/inline-images/32.png\" />\r\n<p>Available at:&nbsp;<a href=\"http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf\">http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf</a></p>\r\n','basic_html'),('indicator',0,432,441,'en',0,'<img alt=\"Extract from Sigakis et al. (2013) (p. 528).\" data-align=\"center\" data-caption=\"Extract from Sigakis et al. (2013) (p. 528).\" data-entity-type=\"file\" data-entity-uuid=\"c9334010-a380-4d31-bc05-f156d15f3212\" src=\"/sites/default/files/inline-images/34.1.png\" /><img alt=\"Extract from Sigakis et al. (2013) (p. 528).\" data-align=\"center\" data-caption=\"Extract from Sigakis et al. (2013) (p. 528).\" data-entity-type=\"file\" data-entity-uuid=\"7b118928-5187-47d7-b750-3367b7c83628\" src=\"/sites/default/files/inline-images/34.2.png\" />\r\n<p>Available at:&nbsp;<a href=\"http://anesthesiology.pubs.asahq.org/article.aspx?doi=10.1097/ALN.0b013e31829ce6e6\">http://anesthesiology.pubs.asahq.org/article.aspx?doi=10.1097/ALN.0b013e31829ce6e6</a></p>\r\n','basic_html'),('indicator',0,433,442,'en',0,'<img alt=\"Extract from &quot;Khanna et al. (2019) (p. 8).\" data-align=\"center\" data-caption=\"Extract from &quot;Khanna et al. (2019) (p. 8).\" data-entity-type=\"file\" data-entity-uuid=\"cb2ad6c4-cf78-4f6b-85fe-d6f9cabbccf6\" src=\"/sites/default/files/inline-images/35.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.nature.com/articles/s41598-019-41383-y\">https://www.nature.com/articles/s41598-019-41383-y</a></p>\r\n','basic_html'),('indicator',0,435,444,'en',0,'<p>NCCN Guidelines for Patients&nbsp;develops research activities in supporting patients through guidelines and tools.</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.nccn.org/patients/guidelines/cancers.aspx\">https://www.nccn.org/patients/guidelines/cancers.aspx</a></p>\r\n','basic_html'),('indicator',0,436,445,'en',0,'<img alt=\"Extract from Prieto &amp; Sacristán (2013) (p. 7).\" data-align=\"center\" data-caption=\"Extract from Prieto &amp;amp; Sacristán (2013) (p. 7).\" data-entity-type=\"file\" data-entity-uuid=\"7fea882e-bc63-427d-a6a9-3b0ebc6aa4cc\" src=\"/sites/default/files/inline-images/38.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-1-80\">https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-1-80</a></p>\r\n','basic_html'),('indicator',0,437,446,'en',0,'<p>Example for percentage of&nbsp;deaths due to multiple sclerosis:</p>\r\n<img alt=\"Figure 2 of Scalfari, A., Knappertz, V., Cutter, G., Goodin, D. S., Ashton, R., &amp; Ebers, G. C. (2013). Mortality in patients with multiple sclerosis. Neurology, 81(2), 184-192. (p. 188). \" data-align=\"center\" data-caption=\"Figure 2 of Scalfari, A., Knappertz, V., Cutter, G., Goodin, D. S., Ashton, R., &amp;amp; Ebers, G. C. (2013). Mortality in patients with multiple sclerosis. Neurology, 81(2), 184-192. (p. 188).&amp;nbsp;\" data-entity-type=\"file\" data-entity-uuid=\"0af90ae2-1c21-4356-b94e-faf661bc3dc0\" src=\"/sites/default/files/inline-images/39.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://n.neurology.org/content/81/2/184.short\">https://n.neurology.org/content/81/2/184.short</a></p>\r\n','basic_html'),('indicator',0,440,449,'en',0,'<img alt=\"Extract from Ottawa Public Health Strategic Direction A Background Document 2016 (p. 15).\" data-align=\"center\" data-caption=\"Extract from Ottawa Public Health Strategic Direction A Background Document 2016 (p. 15).\" data-entity-type=\"file\" data-entity-uuid=\"e98f459c-f340-41ff-a370-e841cf9dc37a\" src=\"/sites/default/files/inline-images/42.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.ottawapublichealth.ca/en/reports-research-and-statistics/resources/Documents/fostering_mental_health_in_our_community_external_acc_final_en.pdf\">https://www.ottawapublichealth.ca/en/reports-research-and-statistics/resources/Documents/fostering_mental_health_in_our_community_external_acc_final_en.pdf</a></p>\r\n','basic_html'),('indicator',0,441,450,'en',0,'<img alt=\"Extract from Sanofi CSR report 2013 (p. 30).\" data-align=\"center\" data-caption=\"Extract from Sanofi CSR report 2013 (p. 30).\" data-entity-type=\"file\" data-entity-uuid=\"eabeeae2-af6c-4f5e-9cfc-3f85dd37ea48\" src=\"/sites/default/files/inline-images/43.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf</a></p>\r\n','basic_html'),('indicator',0,442,451,'en',0,'<p>For the classified list of articles, see&nbsp;Cancer Research UK Manchester Institute Scientific Report 2018 (p. 62-69).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.cruk.manchester.ac.uk/Portals/18/Documents/Annual%20Report/CRUK-Manchester-Annual-Report-2018-web.pdf\">https://www.cruk.manchester.ac.uk/Portals/18/Documents/Annual%20Report/CRUK-Manchester-Annual-Report-2018-web.pdf</a></p>\r\n\r\n<p><br />\r\nFor the number of articles and percentage of articles in high-impact journals, see&nbsp;University of Limerick Health Research Institute Annual Report 2017:</p>\r\n<img alt=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 20).\" data-align=\"center\" data-caption=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 20).\" data-entity-type=\"file\" data-entity-uuid=\"f85c0980-d4de-4d58-871f-12cc32459bf4\" src=\"/sites/default/files/inline-images/44.png\" />\r\n<p>Available at:<a href=\"https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf\">https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf</a></p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,443,452,'en',0,'<p>For the number of international collaborating organizations:</p>\r\n<img alt=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 21)\" data-align=\"center\" data-caption=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 21)\" data-entity-type=\"file\" data-entity-uuid=\"7233431e-0a9e-459e-97cd-56f8d8b30b86\" src=\"/sites/default/files/inline-images/45.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf\">https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf</a></p>\r\n','basic_html'),('indicator',0,444,453,'en',0,'<p>For the share of OA publications in Europe:</p>\r\n<img alt=\"Extract from MoRRI, The evolution of Responsible Research and Innovation in Europe: The MoRRI indicators report (p. 64).\" data-align=\"center\" data-caption=\"Extract from MoRRI, The evolution of Responsible Research and Innovation in Europe: The MoRRI indicators report (p. 64).\" data-entity-type=\"file\" data-entity-uuid=\"a181d7d8-2b33-402c-8f78-31fc3a3c5719\" src=\"/sites/default/files/inline-images/46_0.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.rri-tools.eu/-/the-evolution-of-responsible-research-and-innovation-in-europe-the-morri-indicators-report\">https://www.rri-tools.eu/-/the-evolution-of-responsible-research-and-innovation-in-europe-the-morri-indicators-report</a></p>\r\n','basic_html'),('indicator',0,446,455,'en',0,'<img alt=\"Example on how to obtain number of citations using Google Scholar.\" data-align=\"center\" data-caption=\"Example on how to obtain number of citations using Google Scholar.\" data-entity-type=\"file\" data-entity-uuid=\"7868384e-2859-4bb2-91ca-dcd8e04c2dc7\" src=\"/sites/default/files/inline-images/48.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://scholar.google.com\">https://scholar.google.com</a></p>\r\n','basic_html'),('indicator',0,449,458,'en',0,'<p>See the Max-Planck-Gesellschaft newsroom:&nbsp;<a href=\" https://www.mpg.de/research\"> https://www.mpg.de/research</a></p>\r\n\r\n<p>It indicates news, events, articles, podcasts, and videos by categories as well as latest science magazines.</p>\r\n','basic_html'),('indicator',0,454,463,'en',0,'<p>For a description of the structure and functions of ethical committees&nbsp;see:</p>\r\n\r\n<p>1) \"Research ethics committees\" (World Health Organization, pp. 11-15).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.who.int/ethics/Ethics_basic_concepts_ENG.pdf\">https://www.who.int/ethics/Ethics_basic_concepts_ENG.pdf</a></p>\r\n\r\n<p>2) \"Guide for Research Ethics Committee Members\" (Council of Europe, pp. 15-26).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.coe.int/t/dg3/healthbioethic/activities/02_biomedical_research_en/Guide/Guide_EN.pdf\">https://www.coe.int/t/dg3/healthbioethic/activities/02_biomedical_research_en/Guide/Guide_EN.pdf</a></p>\r\n','basic_html'),('indicator',0,457,466,'en',0,'<img alt=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 24).\" data-align=\"center\" data-caption=\"Extract from University of Limerick Health Research Institute Annual Report 2017 (p. 24).\" data-entity-type=\"file\" data-entity-uuid=\"0eb29c5b-7840-45e0-b250-17eba0aa37a5\" src=\"/sites/default/files/inline-images/60.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf\">https://www.ul.ie/hri/sites/hri/files/user_media/documents/HRI_Annual%20Report%202017%20-%20Final.pdf</a></p>\r\n','basic_html'),('indicator',0,458,467,'en',0,'<p>See ERA-Net for Research Programmes on Rare Diseases; European Research Projects on External Insults to the Nervous System:</p>\r\n\r\n<p><a href=\"http://www.erare.eu/joint-call/1st-joint-call-european-joint-programme-rare-diseases-jtc-2019\">http://www.erare.eu/joint-call/1st-joint-call-european-joint-programme-rare-diseases-jtc-2019</a></p>\r\n','basic_html'),('indicator',0,459,468,'en',0,'<img alt=\"Extract from Public Health Wales Research Strategy 2015-2018 (p. 4)\" data-align=\"center\" data-caption=\"Extract from Public Health Wales Research Strategy 2015-2018 (p. 4)\" data-entity-type=\"file\" data-entity-uuid=\"08a3c9ea-7f1c-4c7b-89d1-123b61a90ff2\" src=\"/sites/default/files/inline-images/62.png\" />\r\n<p>Available at: &nbsp;<a href=\"https://research.publichealthnetwork.cymru/files/7014/8708/7189/PHW_Research_Strategy_report.pdf\">https://research.publichealthnetwork.cymru/files/7014/8708/7189/PHW_Research_Strategy_report.pdf</a></p>\r\n','basic_html'),('indicator',0,460,469,'en',0,'<img alt=\"Extract from FIND Annual Report 2013 (p. 5).\" data-align=\"center\" data-caption=\"Extract from FIND Annual Report 2013 (p. 5).\" data-entity-type=\"file\" data-entity-uuid=\"bd7d3594-fdbd-4003-877d-f59e23d3d842\" src=\"/sites/default/files/inline-images/63.1.png\" /><img alt=\"Extract from FIND Annual Report 2013 (p. 10).\" data-align=\"center\" data-caption=\"Extract from FIND Annual Report 2013 (p. 10).\" data-entity-type=\"file\" data-entity-uuid=\"64689d9b-566d-4dfa-a11f-9551645c1c59\" src=\"/sites/default/files/inline-images/63.2.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.finddx.org/wp-content/uploads/2016/02/Annual-report_2013.pdf\">https://www.finddx.org/wp-content/uploads/2016/02/Annual-report_2013.pdf</a></p>\r\n','basic_html'),('indicator',0,463,472,'en',0,'<p>Breast International Group - Annual Report 2016, (pp. 3-7).<br />\r\nAvailable at:&nbsp;<a href=\"https://research.bigagainstbreastcancer.org/sites/default/files/big_ar_2016_-_final_final_0.pdf\">https://research.bigagainstbreastcancer.org/sites/default/files/big_ar_2016_-_final_final_0.pdf</a></p>\r\n','basic_html'),('indicator',0,466,475,'en',0,'<p>&nbsp;</p>\r\n<img alt=\"Extract from PHW Research Strategy 2015-2018 (p. 11)\" data-align=\"center\" data-caption=\"Extract from Public Health Wales Research Strategy 2015-2018 (p. 11)\" data-entity-type=\"file\" data-entity-uuid=\"961f5be7-ef60-4af4-beda-2ba8232f5af3\" src=\"/sites/default/files/inline-images/69.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://research.publichealthnetwork.cymru/files/7014/8708/7189/PHW_Research_Strategy_report.pdf\">https://research.publichealthnetwork.cymru/files/7014/8708/7189/PHW_Research_Strategy_report.pdf</a></p>\r\n','basic_html'),('indicator',0,472,481,'en',0,'<p>For the number of patens owned and awarded:</p>\r\n<img alt=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 32).\" data-align=\"center\" data-caption=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 32).\" data-entity-type=\"file\" data-entity-uuid=\"44c09851-9ad9-4d1c-b352-05b9cac9b0d5\" src=\"/sites/default/files/inline-images/75.1.png\" /><img alt=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 33).\" data-align=\"center\" data-caption=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 33).\" data-entity-type=\"file\" data-entity-uuid=\"03fbf964-f064-4b33-9370-f47dae0d056b\" src=\"/sites/default/files/inline-images/75.2.png\" />\r\n<p>&nbsp;</p>\r\n\r\n<p>For the classification of patens based on their expiration date and country:</p>\r\n<img alt=\"Extract from Bayer Annual Report 2018 (p. 40).\" data-align=\"center\" data-caption=\"Extract from Bayer Annual Report 2018 (p. 40).\" data-entity-type=\"file\" data-entity-uuid=\"d35b36ac-62a5-4643-8dba-9291d86dd73e\" src=\"/sites/default/files/inline-images/75.3.png\" />\r\n<p>&nbsp;</p>\r\n\r\n<p>For the classification of patents base don whether they are provisonally filled or awarded:</p>\r\n<img alt=\"Extract from Australia\'s Medical Research Institute Snapshot 2018 (p. 20)\" data-align=\"center\" data-caption=\"Extract from Australia\'s Medical Research Institute Snapshot 2018 (p. 20)\" data-entity-type=\"file\" data-entity-uuid=\"849a3126-b821-4b7a-af20-57cfed40a87c\" src=\"/sites/default/files/inline-images/75.4.png\" />\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,473,482,'en',0,'<p>List of projects that are in Phase III clinical trials in Novartis:</p>\r\n<img alt=\"Extract from Novartis Annual Report 2018 (p. 65).\" data-align=\"center\" data-caption=\"Extract from Novartis Annual Report 2018 (p. 65).\" data-entity-type=\"file\" data-entity-uuid=\"032c4c69-5334-4f70-8493-20490c1b2904\" src=\"/sites/default/files/inline-images/76.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2018-en.pdf\">https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2018-en.pdf</a></p>\r\n','basic_html'),('indicator',0,474,483,'en',0,'<p>European Medicines Agency Stakeholder Engagement report 2017 (pp. 5-7).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2017_en.pdf\">https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2017_en.pdf</a></p>\r\n','basic_html'),('indicator',0,475,484,'en',0,'<p>For the full list of products and drugs, see&nbsp;GSK Annual Report 2018 (p. 235-240).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.gsk.com/media/5349/annual-report-2018.pdf\">https://www.gsk.com/media/5349/annual-report-2018.pdf</a></p>\r\n','basic_html'),('indicator',0,477,486,'en',0,'<p>Association of Australian Medical Research Institutes Snapshot 2018 (p. 20)</p>\r\n<img alt=\"Extract from Australia\'s Medical Research Institute Snapshot 2018 (p. 20).\" data-align=\"center\" data-caption=\"Extract from Australia\'s Medical Research Institute Snapshot 2018 (p. 20).\" data-entity-type=\"file\" data-entity-uuid=\"8f25ba45-d19f-4006-b567-2c987533926b\" src=\"/sites/default/files/inline-images/81.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://aamri.org.au/wp-content/uploads/2018/09/2018_AAMRI_Members_Snapshot_Report-final.pdf\">https://aamri.org.au/wp-content/uploads/2018/09/2018_AAMRI_Members_Snapshot_Report-final.pdf</a></p>\r\n','basic_html'),('indicator',0,480,489,'en',0,'<p><img alt=\"Source: IMI Innovative Medicines Initiative Annual Report 2017\" data-entity-type=\"file\" data-entity-uuid=\"a9875d79-b458-41d9-bcc3-005a28da0b7b\" src=\"/sites/default/files/inline-images/84.png\" /></p>\r\n\r\n<p>Extract from IMI Innovative Medicines Initiative Annual Report 2017 (p. 166)</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.imi.europa.eu/sites/default/files/uploads/documents/About-IMI/Governance/Governing-Board/IMI2-GB-DEC-2018-17_Decision%20AAR%202017-GB%20Assessment_signed%2026JUN.pdf\">https://www.imi.europa.eu/sites/default/files/uploads/documents/About-IMI/Governance/Governing-Board/IMI2-GB-DEC-2018-17_Decision%20AAR%202017-GB%20Assessment_signed%2026JUN.pdf</a></p>\r\n','basic_html'),('indicator',0,481,490,'en',0,'<img alt=\"Extract from Era-net Neuron impact report (pp. 17).\" data-align=\"center\" data-caption=\"Extract from Era-net Neuron impact report (pp. 17)\" data-entity-type=\"file\" data-entity-uuid=\"bc38cb7d-1dc9-48f6-bdf9-fab3c2ad8af9\" src=\"/sites/default/files/inline-images/85.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.neuron-eranet.eu/_media/JTC2011_Impact-Report_final.pdf\">https://www.neuron-eranet.eu/_media/JTC2011_Impact-Report_final.pdf</a></p>\r\n','basic_html'),('indicator',0,483,492,'en',0,'<p>For a list of awards (not the total number)&nbsp;see Fraunhofer Institutes Annual Report 2017 (pp. 101-103).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf\">https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf</a></p>\r\n','basic_html'),('indicator',0,484,493,'en',0,'<img alt=\"Extract from Vall d\'Hebron Institute of Research Strategic Plan 2011-15 &quot;Five years committed to people\'s health&quot; (p. 34).\" data-align=\"center\" data-caption=\"Extract from Vall d\'Hebron Institute of Research Strategic Plan 2011-15 &quot;Five years committed to people\'s health&quot; (p. 34).\" data-entity-type=\"file\" data-entity-uuid=\"bb50acb8-86cd-47ef-aa23-e6d6fdf29011\" src=\"/sites/default/files/inline-images/88.png\" />\r\n<p>Available at: <a href=\"http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf\">http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf</a>&nbsp;</p>\r\n','basic_html'),('indicator',0,485,494,'en',0,'<p>Fraunhofer Institutes Annual Report 2017 (pp. 104-115).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf\">https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf</a></p>\r\n','basic_html'),('indicator',0,486,495,'en',0,'<img alt=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 37).\" data-align=\"center\" data-caption=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 37).\" data-entity-type=\"file\" data-entity-uuid=\"10a191f0-b382-4266-98b9-963228564589\" src=\"/sites/default/files/inline-images/90.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf\">https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf</a></p>\r\n','basic_html'),('indicator',0,487,496,'en',0,'<img alt=\"Extract from Fraunhofer Institutes Annual Report 2017 (p. 37).\" data-align=\"center\" data-entity-type=\"file\" data-entity-uuid=\"611288c1-51ad-49ae-aba5-1b5172b9c461\" src=\"/sites/default/files/inline-images/91.png\" />\r\n<p>Extract from Fraunhofer Institutes Annual Report 2017 (p. 37).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf\">https://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/fraunhofer-annual-report-2017-future-of-work.pdf</a></p>\r\n','basic_html'),('indicator',0,488,497,'en',0,'<p>U.S. Department of Health &amp; Human Services:</p>\r\n\r\n<p><a href=\"https://report.nih.gov/categorical_spending_project_listing.aspx?FY=2015&amp;ARRA=N&amp;DCat=Multiple%20Sclerosis\">https://report.nih.gov/categorical_spending_project_listing.aspx?FY=2015&amp;ARRA=N&amp;DCat=Multiple%20Sclerosis</a></p>\r\n','basic_html'),('indicator',0,489,498,'en',0,'<p>Vall d\'Hebron Institue of Research Strategic Plan 2011-15, section&nbsp;\"The organizational basis of success\"&nbsp;(pp. 51-57).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf\">http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf</a></p>\r\n','basic_html'),('indicator',0,491,500,'en',0,'<p>Vall d\'Hebron Institue of Research Strategic Plan 2011-15 \"Five years committed to people\'s health\" (pp. 52-55).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf\">http://www.vhir.org/portal1/Global/pdf/memoria/Memoria_PE_201115.pdf</a></p>\r\n','basic_html'),('indicator',0,493,502,'en',0,'<p>See&nbsp;Proctor et al. (2015) (p. 8-10).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://implementationscience.biomedcentral.com/articles/10.1186/s13012-015-0274-5\">https://implementationscience.biomedcentral.com/articles/10.1186/s13012-015-0274-5</a></p>\r\n','basic_html'),('indicator',0,494,503,'en',0,'<img alt=\"Extract from European Medicines Agency - Stakeholder Engagement Report 2017 (p. 21).\" data-align=\"center\" data-caption=\"Extract from European Medicines Agency - Stakeholder Engagement Report 2017 (p. 21).\" data-entity-type=\"file\" data-entity-uuid=\"76d4587d-272f-4b1a-978f-a05b0ef7f24a\" src=\"/sites/default/files/inline-images/98.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2017_en.pdf\">https://www.ema.europa.eu/en/documents/report/stakeholder-engagement-report-2017_en.pdf</a></p>\r\n\r\n<p><br />\r\nThe example presents different analyses of the individuals and the events related to the different stakeholder engagement activities.</p>\r\n','basic_html'),('indicator',0,495,504,'en',0,'<img alt=\"Extract from European Medicines Agency - Stakeholder Engagement Report 2017 (p. 18).\" data-align=\"center\" data-caption=\"Extract from European Medicines Agency - Stakeholder Engagement Report 2017 (p. 18)\" data-entity-type=\"file\" data-entity-uuid=\"cab507ed-9ea9-4316-bc86-f8415f11165a\" src=\"/sites/default/files/inline-images/99.png\" />\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,497,506,'en',0,'<p>See the \"Corporate Reputation of Pharma in 2018 - the Global Patient Perspective\" (p. 6-8).</p>\r\n\r\n<p>Available <a href=\"https://www.lundbeck.com/upload/global/files/pdf/features/PATIENTVIEW%20PRESS%20RELEASE%20APRIL%202018.pdf\">https://www.lundbeck.com/upload/global/files/pdf/features/PATIENTVIEW%20PRESS%20RELEASE%20APRIL%202018.pdf</a>at:&nbsp;</p>\r\n','basic_html'),('indicator',0,498,507,'en',0,'<img alt=\"Extract from GSK Annual Report 2018 (p. 244).\" data-align=\"center\" data-caption=\"Extract from GSK Annual Report 2018 (p. 244).\" data-entity-type=\"file\" data-entity-uuid=\"d6f8ec55-89a5-4628-a232-187ee9fe45bf\" src=\"/sites/default/files/inline-images/102.png\" />\r\n<p>Available at: <a href=\"https://www.gsk.com/media/5349/annual-report-2018.pdf\">https://www.gsk.com/media/5349/annual-report-2018.pdf</a></p>\r\n\r\n<p>Also, see the \"Code of practices for the pharmaceutical industry 2016\" (see Sections 21 and 22 pp. 32-34).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=11&amp;ved=2ahUKEwj4qoro2YLnAhWP3eAKHSfVBSMQFjAKegQIBhAC&amp;url=http%3A%2F%2Fwww.codigofarmaindustria.org%2Fservlet%2Fsarfi%2Fdocs%2FPRODF117806.pdf&amp;usg=AOvVaw2fmCHiONPxylcGOch_7J9F\">https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=11&amp;ved=2ahUKEwj4qoro2YLnAhWP3eAKHSfVBSMQFjAKegQIBhAC&amp;url=http%3A%2F%2Fwww.codigofarmaindustria.org%2Fservlet%2Fsarfi%2Fdocs%2FPRODF117806.pdf&amp;usg=AOvVaw2fmCHiONPxylcGOch_7J9F</a></p>\r\n','basic_html'),('indicator',0,499,508,'en',0,'<img alt=\"Extract from Sanofi CSR report 2013 (p. 105).\" data-align=\"center\" data-caption=\"Extract from Sanofi CSR report 2013 (p. 105).\" data-entity-type=\"file\" data-entity-uuid=\"712b22a5-70e9-40a3-9f3e-638796bdcb70\" src=\"/sites/default/files/inline-images/103.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf</a></p>\r\n','basic_html'),('indicator',0,500,509,'en',0,'<p>See Sanofi-Fundamental human rights at work available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/download-center/Fundamental-Human-Rights-at-work-2019.pdf\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/download-center/Fundamental-Human-Rights-at-work-2019.pdf</a></p>\r\n','basic_html'),('indicator',0,501,510,'en',0,'<img alt=\"Extract from Novartis Corporate Responsibility Report 2017 (p. 47).\" data-align=\"center\" data-caption=\"Extract from Novartis Corporate Responsibility Report 2017 (p. 47).\" data-entity-type=\"file\" data-entity-uuid=\"575188b3-ce4f-44fb-ac45-8f14997729ae\" src=\"/sites/default/files/inline-images/105.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.novartis.com/sites/www.novartis.com/files/novartis-cr-performance-report-2017.pdf\">https://www.novartis.com/sites/www.novartis.com/files/novartis-cr-performance-report-2017.pdf</a></p>\r\n','basic_html'),('indicator',0,502,511,'en',0,'<img alt=\"Extract from Sanofi Turky Sustainability Report 2017 (p. 89)\" data-align=\"center\" data-caption=\"Extract from Sanofi Turky Sustainability Report 2017 (p. 89).\" data-entity-type=\"file\" data-entity-uuid=\"7fac5f8d-2f5d-43d7-ac5e-b293f18cfa5f\" src=\"/sites/default/files/inline-images/106.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/download-center/Sanofi-Turkey-Sustainability-Report-2017.pdf?la=en\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/download-center/Sanofi-Turkey-Sustainability-Report-2017.pdf?la=en</a></p>\r\n','basic_html'),('indicator',0,505,514,'en',0,'<img alt=\"Extract from GSK Annual Report 2018 (p. 11).\" data-align=\"center\" data-caption=\"Extract from GSK Annual Report 2018 (p. 11).\" data-entity-type=\"file\" data-entity-uuid=\"a1ee004e-943b-49c2-8da0-26a7e7e0cb45\" src=\"/sites/default/files/inline-images/109.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.gsk.com/media/5349/annual-report-2018.pdf\">https://www.gsk.com/media/5349/annual-report-2018.pdf</a></p>\r\n','basic_html'),('indicator',0,506,515,'en',0,'<img alt=\"Extract from Sanofi CSR report 2013 (p. 51).\" data-align=\"center\" data-caption=\"Extract from Sanofi CSR report 2013 (p. 51).\" data-entity-type=\"file\" data-entity-uuid=\"a754d9e4-7c3b-4ec5-ac24-eacccc458e45\" src=\"/sites/default/files/inline-images/110.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf\">https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/A-H/CSR_Report_2013.pdf</a></p>\r\n','basic_html'),('indicator',0,507,516,'en',0,'<img alt=\"Extract from Takeda Sustainable Value Report 2018 (p. 61).\" data-align=\"center\" data-caption=\"Extract from Takeda Sustainable Value Report 2018 (p. 61).\" data-entity-type=\"file\" data-entity-uuid=\"258cdf5e-1de0-4571-a4ca-bba994dffc09\" src=\"/sites/default/files/inline-images/111.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.takeda.com/siteassets/system/csr/sustainable-value-report/report_2018_en.pdf\">https://www.takeda.com/siteassets/system/csr/sustainable-value-report/report_2018_en.pdf</a></p>\r\n','basic_html'),('indicator',0,508,517,'en',0,'<p>&nbsp;</p>\r\n<img alt=\"Extract from Novartis Health, Safety and Environment (HSE) Data 2018\" data-align=\"center\" data-caption=\"Extract from Novartis Health, Safety and Environment (HSE) Data 2018.\" data-entity-type=\"file\" data-entity-uuid=\"7e9a28a8-70ac-441a-b437-a60cef97c4e9\" src=\"/sites/default/files/inline-images/Captura%20de%20pantalla%202019-12-27%20a%20las%2011.03.19.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.novartis.com/sites/www.novartis.com/files/novartis-hse-data-2018-restated.pdf\">https://www.novartis.com/sites/www.novartis.com/files/novartis-hse-data-2018-restated.pdf</a></p>\r\n','basic_html'),('indicator',0,510,519,'en',0,'<img alt=\"Extract from Ottawa Public Health Strategic Direction A Background Document September 2016 (p. 14).\" data-align=\"center\" data-caption=\"Extract from Ottawa Public Health Strategic Direction A Background Document September 2016 (p. 14).\" data-entity-type=\"file\" data-entity-uuid=\"5e939ed3-789e-4d2e-919c-8bd643116a66\" src=\"/sites/default/files/inline-images/115.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.ottawapublichealth.ca/en/reports-research-and-statistics/resources/Documents/fostering_mental_health_in_our_community_external_acc_final_en.pdf\">https://www.ottawapublichealth.ca/en/reports-research-and-statistics/resources/Documents/fostering_mental_health_in_our_community_external_acc_final_en.pdf</a></p>\r\n','basic_html'),('indicator',0,547,557,'en',0,'<img alt=\"Extract from Progressive MS Alliance Report Progress 2019 (p. 5).\" data-align=\"center\" data-caption=\"Extract from Progressive MS Alliance Report Progress 2019 (p. 5).\" data-entity-type=\"file\" data-entity-uuid=\"339df70e-f0f3-40a1-9b90-3fb01a17a177\" src=\"/sites/default/files/inline-images/78_0.png\" />\r\n<p>Available at:&nbsp;<a href=\"https://www.progressivemsalliance.org/wp-content/uploads/2019/06/Alliance_Progress_Report_Apr-2019_digital.pdf\">https://www.progressivemsalliance.org/wp-content/uploads/2019/06/Alliance_Progress_Report_Apr-2019_digital.pdf</a></p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html'),('indicator',0,548,558,'en',0,'<p>List of annual sustainability reports of the&nbsp;Fondazione Italiana Sclerosi Multipla&nbsp;(FISM).</p>\r\n\r\n<p>Available at:&nbsp;<a href=\"https://www.aism.it/il_bilancio_sociale\">https://www.aism.it/il_bilancio_sociale</a></p>\r\n','basic_html'),('indicator',0,549,559,'en',0,'<p><span><span><span><span><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,550,560,'en',0,'<p><span><span><span><span><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,551,561,'en',0,'<p><span><span><span><span><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,552,562,'en',0,'<p><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></p>\r\n','basic_html'),('indicator',0,553,563,'en',0,'<p><span><span><span><span><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,554,564,'en',0,'<p><span><span><span><span><span>Brichetto G, Monti Bragadin M, Fiorini S, et al. The hidden information in patient-reported outcomes and clinician-assessed outcomes: multiple sclerosis as a proof of concept of a machine learning approach [published online ahead of print, 2019 Oct 28]. Neurol Sci. 2019;10.1007/s10072-019-04093-x. doi:10.1007/s10072-019-04093-x</span></span></span></span></span></p>\r\n','basic_html'),('indicator',0,585,612,'en',0,'<p>Solaro C, Trabucco E, Signori A, Cella M, Messmer Uccelli M, Brichetto G, Cavalla P, Gironi M, Patti F, Prosperini L. Italian validation of the 12-item multiple sclerosis walking scale. Mult Scler Int. 2015;2015:540828. doi:10.1155/2015/540828. Epub 2015 Mar 26. PubMed PMID: 25883806; PubMed Central PMCID: PMC4391321.</p>\r\n\r\n<p>&nbsp;</p>\r\n','basic_html');

--
-- Table structure for table `node__field_exp_freq_of_data_collectio`
--

CREATE TABLE `node__field_exp_freq_of_data_collectio` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_exp_freq_of_data_collectio_value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_exp_freq_of_data…';

--
-- Dumping data for table `node__field_exp_freq_of_data_collectio`
--

INSERT INTO `node__field_exp_freq_of_data_collectio` VALUES ('indicator',0,399,408,'en',0,'Annually'),('indicator',0,400,409,'en',0,'Annually'),('indicator',0,401,410,'en',0,'Annually'),('indicator',0,402,411,'en',0,'Annually'),('indicator',0,403,412,'en',0,'Annually'),('indicator',0,404,413,'en',0,'Annually'),('indicator',0,405,414,'en',0,'Annually'),('indicator',0,406,415,'en',0,'Annually'),('indicator',0,407,416,'en',0,'Annually'),('indicator',0,408,417,'en',0,'Annually'),('indicator',0,409,418,'en',0,'Monthly/Annually'),('indicator',0,410,419,'en',0,'Annually'),('indicator',0,411,420,'en',0,'Annually'),('indicator',0,412,421,'en',0,'Annually'),('indicator',0,413,422,'en',0,'Triennial'),('indicator',0,414,423,'en',0,'Annually'),('indicator',0,415,424,'en',0,'Annually'),('indicator',0,416,425,'en',0,'Annually'),('indicator',0,417,426,'en',0,'Annually'),('indicator',0,418,427,'en',0,'Annually'),('indicator',0,419,428,'en',0,'Annually'),('indicator',0,420,429,'en',0,'Annually'),('indicator',0,421,430,'en',0,'Annually'),('indicator',0,422,431,'en',0,'Annually'),('indicator',0,423,432,'en',0,'Annually'),('indicator',0,424,433,'en',0,'Annually'),('indicator',0,425,434,'en',0,'Annually'),('indicator',0,426,435,'en',0,'Annually'),('indicator',0,427,436,'en',0,'Annually'),('indicator',0,428,437,'en',0,'Annually'),('indicator',0,429,438,'en',0,'Annually'),('indicator',0,430,439,'en',0,'Annually'),('indicator',0,431,440,'en',0,'Monthly/Annually'),('indicator',0,432,441,'en',0,'Annually'),('indicator',0,433,442,'en',0,'Monthly/Annually'),('indicator',0,434,443,'en',0,'Annually'),('indicator',0,435,444,'en',0,'Annually'),('indicator',0,436,445,'en',0,'Monthly'),('indicator',0,437,446,'en',0,'Annually'),('indicator',0,438,447,'en',0,'Annually'),('indicator',0,439,448,'en',0,'Annually'),('indicator',0,440,449,'en',0,'Annually'),('indicator',0,441,450,'en',0,'Annually'),('indicator',0,442,451,'en',0,'Annually'),('indicator',0,443,452,'en',0,'Annually'),('indicator',0,444,453,'en',0,'Annually'),('indicator',0,445,454,'en',0,'Annually'),('indicator',0,446,455,'en',0,'Annually'),('indicator',0,447,456,'en',0,'It will be automatically managed by specific services. The information is timely'),('indicator',0,448,457,'en',0,'Annually'),('indicator',0,449,458,'en',0,'Annually'),('indicator',0,450,459,'en',0,'Annually'),('indicator',0,451,460,'en',0,'Continuous'),('indicator',0,452,461,'en',0,'Annually'),('indicator',0,453,462,'en',0,'Annually'),('indicator',0,454,463,'en',0,'Annually'),('indicator',0,455,464,'en',0,'Annually'),('indicator',0,456,465,'en',0,'Annually'),('indicator',0,457,466,'en',0,'Annually'),('indicator',0,458,467,'en',0,'Annually'),('indicator',0,459,468,'en',0,'Annually'),('indicator',0,460,469,'en',0,'Annually'),('indicator',0,461,470,'en',0,'Annually'),('indicator',0,462,471,'en',0,'Annually'),('indicator',0,463,472,'en',0,'Annually'),('indicator',0,464,473,'en',0,'Annually'),('indicator',0,465,474,'en',0,'Annually'),('indicator',0,466,475,'en',0,'Annually'),('indicator',0,467,476,'en',0,'Semi-annually'),('indicator',0,468,477,'en',0,'Semi-annually'),('indicator',0,469,478,'en',0,'Semi-annually'),('indicator',0,470,479,'en',0,'Annually'),('indicator',0,471,480,'en',0,'Annually'),('indicator',0,472,481,'en',0,'Annually'),('indicator',0,473,482,'en',0,'Annually'),('indicator',0,474,483,'en',0,'Annually'),('indicator',0,475,484,'en',0,'Annually'),('indicator',0,476,485,'en',0,'Annually'),('indicator',0,477,486,'en',0,'Annually'),('indicator',0,478,487,'en',0,'Annually'),('indicator',0,479,488,'en',0,'Annually'),('indicator',0,480,489,'en',0,'Annually'),('indicator',0,481,490,'en',0,'Annually'),('indicator',0,482,491,'en',0,'Annually'),('indicator',0,483,492,'en',0,'Annually'),('indicator',0,484,493,'en',0,'Annually'),('indicator',0,485,494,'en',0,'Annually'),('indicator',0,486,495,'en',0,'Annually'),('indicator',0,487,496,'en',0,'Annually'),('indicator',0,488,497,'en',0,'Annually'),('indicator',0,489,498,'en',0,'Annually'),('indicator',0,490,499,'en',0,'Every three-month'),('indicator',0,491,500,'en',0,'Annually'),('indicator',0,492,501,'en',0,'Annually'),('indicator',0,493,502,'en',0,'Annually'),('indicator',0,494,503,'en',0,'Annually'),('indicator',0,495,504,'en',0,'Annually'),('indicator',0,496,505,'en',0,'Annually'),('indicator',0,497,506,'en',0,'Annually'),('indicator',0,498,507,'en',0,'Annually'),('indicator',0,499,508,'en',0,'Annually'),('indicator',0,500,509,'en',0,'Annually'),('indicator',0,501,510,'en',0,'Annually'),('indicator',0,502,511,'en',0,'Annually'),('indicator',0,503,512,'en',0,'Annually'),('indicator',0,504,513,'en',0,'Annually'),('indicator',0,505,514,'en',0,'Annually'),('indicator',0,506,515,'en',0,'Annually'),('indicator',0,507,516,'en',0,'Monthly/Annually'),('indicator',0,508,517,'en',0,'Monthly/Annually'),('indicator',0,509,518,'en',0,'Annually'),('indicator',0,510,519,'en',0,'Annually'),('indicator',0,512,521,'en',0,'Annually'),('indicator',0,547,557,'en',0,'Annually'),('indicator',0,548,558,'en',0,'Annually'),('indicator',0,549,559,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,550,560,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,551,561,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,552,562,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,553,563,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,554,564,'en',0,'It depends on the assessment (usually at every assessment point)'),('indicator',0,585,612,'en',0,'It depends on the assessment (usually at every assessment point)');

--
-- Table structure for table `node__field_expected_frequency_of_data`
--

CREATE TABLE `node__field_expected_frequency_of_data` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_expected_frequency_of_data_value` longtext NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_expected_frequency_of…';

--
-- Dumping data for table `node__field_expected_frequency_of_data`
--

INSERT INTO `node__field_expected_frequency_of_data` VALUES ('indicator',0,399,408,'en',0,'Annually'),('indicator',0,400,409,'en',0,'Annually'),('indicator',0,401,410,'en',0,'Annually'),('indicator',0,402,411,'en',0,'Annually'),('indicator',0,403,412,'en',0,'Annually'),('indicator',0,404,413,'en',0,'Annually'),('indicator',0,405,414,'en',0,'Annually'),('indicator',0,406,415,'en',0,'Annually'),('indicator',0,407,416,'en',0,'Annually'),('indicator',0,408,417,'en',0,'Annually'),('indicator',0,409,418,'en',0,'Annually'),('indicator',0,410,419,'en',0,'Annually'),('indicator',0,411,420,'en',0,'Annually'),('indicator',0,412,421,'en',0,'Annually'),('indicator',0,413,422,'en',0,'Triennial'),('indicator',0,414,423,'en',0,'Annually'),('indicator',0,415,424,'en',0,'Annually'),('indicator',0,416,425,'en',0,'Annually'),('indicator',0,417,426,'en',0,'Annually'),('indicator',0,418,427,'en',0,'Annually'),('indicator',0,419,428,'en',0,'Annually'),('indicator',0,420,429,'en',0,'Annually'),('indicator',0,421,430,'en',0,'Annually'),('indicator',0,422,431,'en',0,'Annually'),('indicator',0,423,432,'en',0,'Annually'),('indicator',0,424,433,'en',0,'Annually'),('indicator',0,425,434,'en',0,'Annually'),('indicator',0,426,435,'en',0,'Annually'),('indicator',0,427,436,'en',0,'Annually'),('indicator',0,428,437,'en',0,'Annually'),('indicator',0,429,438,'en',0,'Annually'),('indicator',0,430,439,'en',0,'Annually'),('indicator',0,431,440,'en',0,'Semi-annually'),('indicator',0,432,441,'en',0,'Annually'),('indicator',0,433,442,'en',0,'Annually'),('indicator',0,434,443,'en',0,'Annually'),('indicator',0,435,444,'en',0,'Annually'),('indicator',0,436,445,'en',0,'Monthly'),('indicator',0,437,446,'en',0,'Annually'),('indicator',0,438,447,'en',0,'Annually'),('indicator',0,439,448,'en',0,'Annually'),('indicator',0,440,449,'en',0,'Annually'),('indicator',0,441,450,'en',0,'Annually'),('indicator',0,442,451,'en',0,'Annually'),('indicator',0,443,452,'en',0,'Annually'),('indicator',0,444,453,'en',0,'Annually'),('indicator',0,445,454,'en',0,'Annually'),('indicator',0,446,455,'en',0,'Annually'),('indicator',0,447,456,'en',0,'Annually'),('indicator',0,448,457,'en',0,'Annually'),('indicator',0,449,458,'en',0,'Annually'),('indicator',0,450,459,'en',0,'Annually'),('indicator',0,451,460,'en',0,'Monthly'),('indicator',0,452,461,'en',0,'Annually'),('indicator',0,453,462,'en',0,'Annually'),('indicator',0,454,463,'en',0,'Annually'),('indicator',0,455,464,'en',0,'Annually'),('indicator',0,456,465,'en',0,'Annually'),('indicator',0,457,466,'en',0,'Annually'),('indicator',0,458,467,'en',0,'Annually'),('indicator',0,459,468,'en',0,'Annually'),('indicator',0,460,469,'en',0,'Annually'),('indicator',0,461,470,'en',0,'Annually'),('indicator',0,462,471,'en',0,'Annually'),('indicator',0,463,472,'en',0,'Annually'),('indicator',0,464,473,'en',0,'Annually'),('indicator',0,465,474,'en',0,'Annually'),('indicator',0,466,475,'en',0,'Annually'),('indicator',0,467,476,'en',0,'Annually'),('indicator',0,468,477,'en',0,'Annually'),('indicator',0,469,478,'en',0,'Annually'),('indicator',0,470,479,'en',0,'Annually'),('indicator',0,471,480,'en',0,'Annually'),('indicator',0,472,481,'en',0,'Annually'),('indicator',0,473,482,'en',0,'Annually'),('indicator',0,474,483,'en',0,'Annually'),('indicator',0,475,484,'en',0,'Annually'),('indicator',0,476,485,'en',0,'Annually'),('indicator',0,477,486,'en',0,'Annually'),('indicator',0,478,487,'en',0,'Annually'),('indicator',0,479,488,'en',0,'Annually'),('indicator',0,480,489,'en',0,'Annually'),('indicator',0,481,490,'en',0,'Annually'),('indicator',0,482,491,'en',0,'Annually'),('indicator',0,483,492,'en',0,'Annually'),('indicator',0,484,493,'en',0,'Annually'),('indicator',0,485,494,'en',0,'Annually'),('indicator',0,486,495,'en',0,'Annually'),('indicator',0,487,496,'en',0,'Annually'),('indicator',0,488,497,'en',0,'Annually'),('indicator',0,489,498,'en',0,'Annually'),('indicator',0,490,499,'en',0,'Annually'),('indicator',0,491,500,'en',0,'Annually'),('indicator',0,492,501,'en',0,'Annually'),('indicator',0,493,502,'en',0,'Annually'),('indicator',0,494,503,'en',0,'Annually'),('indicator',0,495,504,'en',0,'Annually'),('indicator',0,496,505,'en',0,'Annually'),('indicator',0,497,506,'en',0,'Annually'),('indicator',0,498,507,'en',0,'Annually'),('indicator',0,499,508,'en',0,'Annually'),('indicator',0,500,509,'en',0,'Annually'),('indicator',0,501,510,'en',0,'Annually'),('indicator',0,502,511,'en',0,'Annually'),('indicator',0,503,512,'en',0,'Annually'),('indicator',0,504,513,'en',0,'Annually'),('indicator',0,505,514,'en',0,'Annually'),('indicator',0,506,515,'en',0,'Annually'),('indicator',0,507,516,'en',0,'Annually'),('indicator',0,508,517,'en',0,'Annually'),('indicator',0,509,518,'en',0,'Annually'),('indicator',0,510,519,'en',0,'Annually'),('indicator',0,512,521,'en',0,'Annually'),('indicator',0,547,557,'en',0,'Annually'),('indicator',0,548,558,'en',0,'Annually'),('indicator',0,549,559,'en',0,'At the end of overall data collection and analysis'),('indicator',0,550,560,'en',0,'At the end of overall data collection and analysis'),('indicator',0,551,561,'en',0,'At the end of overall data collection and analysis'),('indicator',0,552,562,'en',0,'At the end of overall data collection and analysis'),('indicator',0,553,563,'en',0,'At the end of overall data collection and analysis'),('indicator',0,554,564,'en',0,'At the end of overall data collection and analysis'),('indicator',0,585,612,'en',0,'At the end of overall data collection and analysis');

--
-- Table structure for table `node__field_funding_research`
--

CREATE TABLE `node__field_funding_research` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_funding_research_value` tinyint(4) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_funding_research.';

--
-- Dumping data for table `node__field_funding_research`
--

INSERT INTO `node__field_funding_research` VALUES ('initiative',0,1,7,'en',0,0),('initiative',0,306,314,'en',0,1),('initiative',0,307,315,'en',0,1),('initiative',0,309,318,'en',0,1),('initiative',0,310,319,'en',0,0),('initiative',0,516,525,'en',0,1),('initiative',0,518,528,'en',0,1),('initiative',0,519,529,'en',0,0),('initiative',0,520,530,'en',0,0),('initiative',0,521,531,'en',0,0),('initiative',0,522,532,'en',0,0),('initiative',0,523,533,'en',0,1),('initiative',0,524,534,'en',0,1),('initiative',0,525,535,'en',0,0),('initiative',0,526,536,'en',0,1),('initiative',0,527,537,'en',0,1),('initiative',0,528,538,'en',0,1),('initiative',0,529,539,'en',0,1),('initiative',0,530,540,'en',0,0),('initiative',0,531,541,'en',0,1),('initiative',0,534,544,'en',0,0),('initiative',0,535,545,'en',0,0),('initiative',0,536,546,'en',0,0),('initiative',0,537,547,'en',0,0),('initiative',0,538,548,'en',0,1),('initiative',0,539,549,'en',0,1),('initiative',0,540,550,'en',0,0),('initiative',0,541,551,'en',0,1),('initiative',0,542,552,'en',0,0),('initiative',0,543,553,'en',0,1),('initiative',0,544,554,'en',0,0),('initiative',0,545,555,'en',0,0),('initiative',0,546,556,'en',0,0),('initiative',0,555,565,'en',0,1),('initiative',0,556,566,'en',0,0),('initiative',0,557,567,'en',0,0),('initiative',0,564,582,'en',0,1),('initiative',0,572,599,'en',0,1),('initiative',0,589,616,'en',0,0),('initiative',0,590,617,'en',0,1),('initiative',0,592,621,'en',0,1),('initiative',0,593,622,'en',0,1);

--
-- Table structure for table `node__field_geographical_coverage`
--

CREATE TABLE `node__field_geographical_coverage` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_geographical_coverage_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_geographical_coverage_value` (`field_geographical_coverage_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_geographical_coverage.';

--
-- Dumping data for table `node__field_geographical_coverage`
--

INSERT INTO `node__field_geographical_coverage` VALUES ('initiative',0,1,7,'en',0,'Europe'),('initiative',0,1,7,'en',1,'Afghanistan'),('initiative',0,306,314,'en',0,'Afghanistan'),('initiative',0,307,315,'en',0,'Europe'),('initiative',0,309,318,'en',0,'Andorra'),('initiative',0,309,318,'en',1,'Antigua and Barbuda'),('initiative',0,310,319,'en',0,'Afghanistan'),('initiative',0,516,525,'en',0,'Europe'),('initiative',0,518,528,'en',0,'Afghanistan'),('initiative',0,519,529,'en',0,'Afghanistan'),('initiative',0,520,530,'en',0,'Afghanistan'),('initiative',0,521,531,'en',0,'Afghanistan'),('initiative',0,522,532,'en',0,'Europe'),('initiative',0,523,533,'en',0,'Europe'),('initiative',0,524,534,'en',0,'Europe'),('initiative',0,525,535,'en',0,'Europe'),('initiative',0,526,536,'en',0,'Afghanistan'),('initiative',0,527,537,'en',0,'World'),('initiative',0,528,538,'en',0,'Europe'),('initiative',0,528,538,'en',1,'Afghanistan'),('initiative',0,529,539,'en',0,'Argentina'),('initiative',0,529,539,'en',1,'Australia'),('initiative',0,529,539,'en',2,'Austria'),('initiative',0,529,539,'en',3,'Belgium'),('initiative',0,530,540,'en',0,'Andorra'),('initiative',0,530,540,'en',1,'Argentina'),('initiative',0,531,541,'en',0,'World'),('initiative',0,534,544,'en',0,'Italy'),('initiative',0,535,545,'en',0,'World'),('initiative',0,536,546,'en',0,'Europe'),('initiative',0,537,547,'en',0,'Europe'),('initiative',0,538,548,'en',0,'Europe'),('initiative',0,539,549,'en',0,'Europe'),('initiative',0,540,550,'en',0,'Poland'),('initiative',0,541,551,'en',0,'Europe'),('initiative',0,542,552,'en',0,'Europe'),('initiative',0,543,553,'en',0,'World'),('initiative',0,544,554,'en',0,'Czechia (Czech Republic)'),('initiative',0,544,554,'en',1,'Denmark'),('initiative',0,545,555,'en',0,'Europe'),('initiative',0,546,556,'en',0,'Europe'),('initiative',0,555,565,'en',0,'World'),('initiative',0,556,566,'en',0,'Finland'),('initiative',0,557,567,'en',0,'World'),('initiative',0,564,582,'en',0,'Austria'),('initiative',0,572,599,'en',0,'World'),('initiative',0,589,616,'en',0,'Europe'),('initiative',0,590,617,'en',0,'World'),('initiative',0,592,621,'en',0,'World'),('initiative',0,593,622,'en',0,'Europe');

--
-- Table structure for table `node__field_image`
--

CREATE TABLE `node__field_image` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_image_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the file entity.',
  `field_image_alt` varchar(512) DEFAULT NULL COMMENT 'Alternative image text, for the image''s ''alt'' attribute.',
  `field_image_title` varchar(1024) DEFAULT NULL COMMENT 'Image title text, for the image''s ''title'' attribute.',
  `field_image_width` int(10) unsigned DEFAULT NULL COMMENT 'The width of the image in pixels.',
  `field_image_height` int(10) unsigned DEFAULT NULL COMMENT 'The height of the image in pixels.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_image_target_id` (`field_image_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_image.';

--
-- Dumping data for table `node__field_image`
--


--
-- Table structure for table `node__field_indicator`
--

CREATE TABLE `node__field_indicator` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_indicator_target_id` int(10) unsigned NOT NULL COMMENT 'The ID of the target entity.',
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_indicator_target_id` (`field_indicator_target_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_indicator.';

--
-- Dumping data for table `node__field_indicator`
--

INSERT INTO `node__field_indicator` VALUES ('impact_analysis',0,532,542,'en',0,399),('impact_analysis',0,533,543,'en',0,400),('impact_analysis',0,559,577,'en',0,402),('impact_analysis',0,560,578,'en',0,419),('impact_analysis',0,561,579,'en',0,500),('impact_analysis',0,562,580,'en',0,419),('impact_analysis',0,563,581,'en',0,439),('impact_analysis',0,565,583,'en',0,405),('impact_analysis',0,566,584,'en',0,498),('impact_analysis',0,567,585,'en',0,451),('impact_analysis',0,568,586,'en',0,434),('impact_analysis',0,569,587,'en',0,549),('impact_analysis',0,574,601,'en',0,503),('impact_analysis',0,575,602,'en',0,440),('impact_analysis',0,576,603,'en',0,409),('impact_analysis',0,577,604,'en',0,550),('impact_analysis',0,578,605,'en',0,419),('impact_analysis',0,579,606,'en',0,467),('impact_analysis',0,580,607,'en',0,436),('impact_analysis',0,581,608,'en',0,425),('impact_analysis',0,582,609,'en',0,439),('impact_analysis',0,583,610,'en',0,436),('impact_analysis',0,584,611,'en',0,438),('impact_analysis',0,586,613,'en',0,549),('impact_analysis',0,587,614,'en',0,439),('impact_analysis',0,588,615,'en',0,550),('impact_analysis',0,591,620,'en',0,551);

--
-- Table structure for table `node__field_indicator_code`
--

CREATE TABLE `node__field_indicator_code` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_indicator_code_value` int(11) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_indicator_code.';

--
-- Dumping data for table `node__field_indicator_code`
--

INSERT INTO `node__field_indicator_code` VALUES ('indicator',0,399,408,'en',0,1),('indicator',0,400,409,'en',0,2),('indicator',0,401,410,'en',0,3),('indicator',0,402,411,'en',0,4),('indicator',0,403,412,'en',0,5),('indicator',0,404,413,'en',0,6),('indicator',0,405,414,'en',0,7),('indicator',0,406,415,'en',0,8),('indicator',0,407,416,'en',0,9),('indicator',0,408,417,'en',0,10),('indicator',0,409,418,'en',0,11),('indicator',0,410,419,'en',0,12),('indicator',0,411,420,'en',0,13),('indicator',0,412,421,'en',0,14),('indicator',0,413,422,'en',0,15),('indicator',0,414,423,'en',0,16),('indicator',0,415,424,'en',0,17),('indicator',0,416,425,'en',0,18),('indicator',0,417,426,'en',0,19),('indicator',0,418,427,'en',0,20),('indicator',0,419,428,'en',0,21),('indicator',0,420,429,'en',0,22),('indicator',0,421,430,'en',0,23),('indicator',0,422,431,'en',0,24),('indicator',0,423,432,'en',0,25),('indicator',0,424,433,'en',0,26),('indicator',0,425,434,'en',0,27),('indicator',0,426,435,'en',0,28),('indicator',0,427,436,'en',0,29),('indicator',0,428,437,'en',0,30),('indicator',0,429,438,'en',0,31),('indicator',0,430,439,'en',0,32),('indicator',0,431,440,'en',0,33),('indicator',0,432,441,'en',0,34),('indicator',0,433,442,'en',0,35),('indicator',0,434,443,'en',0,36),('indicator',0,435,444,'en',0,37),('indicator',0,436,445,'en',0,38),('indicator',0,437,446,'en',0,39),('indicator',0,438,447,'en',0,40),('indicator',0,439,448,'en',0,41),('indicator',0,440,449,'en',0,42),('indicator',0,441,450,'en',0,43),('indicator',0,442,451,'en',0,44),('indicator',0,443,452,'en',0,45),('indicator',0,444,453,'en',0,46),('indicator',0,445,454,'en',0,47),('indicator',0,446,455,'en',0,48),('indicator',0,447,456,'en',0,49),('indicator',0,448,457,'en',0,50),('indicator',0,449,458,'en',0,51),('indicator',0,450,459,'en',0,52),('indicator',0,451,460,'en',0,53),('indicator',0,452,461,'en',0,55),('indicator',0,453,462,'en',0,56),('indicator',0,454,463,'en',0,57),('indicator',0,455,464,'en',0,58),('indicator',0,456,465,'en',0,59),('indicator',0,457,466,'en',0,60),('indicator',0,458,467,'en',0,61),('indicator',0,459,468,'en',0,62),('indicator',0,460,469,'en',0,63),('indicator',0,461,470,'en',0,64),('indicator',0,462,471,'en',0,65),('indicator',0,463,472,'en',0,66),('indicator',0,464,473,'en',0,67),('indicator',0,465,474,'en',0,68),('indicator',0,466,475,'en',0,69),('indicator',0,467,476,'en',0,70),('indicator',0,468,477,'en',0,71),('indicator',0,469,478,'en',0,72),('indicator',0,470,479,'en',0,73),('indicator',0,471,480,'en',0,74),('indicator',0,472,481,'en',0,75),('indicator',0,473,482,'en',0,76),('indicator',0,474,483,'en',0,77),('indicator',0,475,484,'en',0,79),('indicator',0,476,485,'en',0,80),('indicator',0,477,486,'en',0,81),('indicator',0,478,487,'en',0,82),('indicator',0,479,488,'en',0,83),('indicator',0,480,489,'en',0,84),('indicator',0,481,490,'en',0,85),('indicator',0,482,491,'en',0,86),('indicator',0,483,492,'en',0,87),('indicator',0,484,493,'en',0,88),('indicator',0,485,494,'en',0,89),('indicator',0,486,495,'en',0,90),('indicator',0,487,496,'en',0,91),('indicator',0,488,497,'en',0,92),('indicator',0,489,498,'en',0,93),('indicator',0,490,499,'en',0,94),('indicator',0,491,500,'en',0,95),('indicator',0,492,501,'en',0,96),('indicator',0,493,502,'en',0,97),('indicator',0,494,503,'en',0,98),('indicator',0,495,504,'en',0,99),('indicator',0,496,505,'en',0,100),('indicator',0,497,506,'en',0,101),('indicator',0,498,507,'en',0,102),('indicator',0,499,508,'en',0,103),('indicator',0,500,509,'en',0,104),('indicator',0,501,510,'en',0,105),('indicator',0,502,511,'en',0,106),('indicator',0,503,512,'en',0,107),('indicator',0,504,513,'en',0,108),('indicator',0,505,514,'en',0,109),('indicator',0,506,515,'en',0,110),('indicator',0,507,516,'en',0,111),('indicator',0,508,517,'en',0,113),('indicator',0,509,518,'en',0,114),('indicator',0,510,519,'en',0,115),('indicator',0,512,521,'en',0,54),('indicator',0,547,557,'en',0,78),('indicator',0,548,558,'en',0,112),('indicator',0,549,559,'en',0,183),('indicator',0,550,560,'en',0,184),('indicator',0,551,561,'en',0,185),('indicator',0,552,562,'en',0,186),('indicator',0,553,563,'en',0,181),('indicator',0,554,564,'en',0,154);

--
-- Table structure for table `node__field_indicator_in_use`
--

CREATE TABLE `node__field_indicator_in_use` (
  `bundle` varchar(128) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The field instance bundle to which this row belongs, used when deleting a field instance',
  `deleted` tinyint(4) NOT NULL DEFAULT 0 COMMENT 'A boolean indicating whether this data item has been deleted',
  `entity_id` int(10) unsigned NOT NULL COMMENT 'The entity id this data is attached to',
  `revision_id` int(10) unsigned NOT NULL COMMENT 'The entity revision id this data is attached to',
  `langcode` varchar(32) CHARACTER SET ascii NOT NULL DEFAULT '' COMMENT 'The language code for this data item.',
  `delta` int(10) unsigned NOT NULL COMMENT 'The sequence number for this data item, used for multi-value fields',
  `field_indicator_in_use_value` varchar(255) NOT NULL,
  PRIMARY KEY (`entity_id`,`deleted`,`delta`,`langcode`),
  KEY `bundle` (`bundle`),
  KEY `revision_id` (`revision_id`),
  KEY `field_indicator_in_use_value` (`field_indicator_in_use_value`(191))
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COMMENT='Data storage for node field field_indicator_in_use.';

--
